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 I
I. Samenvatting, Summary, Résumé 
I.1. Samenvatting 
Reeds meer dan 15 jaar wordt routinematig tegen hepatitis B virus (HBV) gevaccineerd. De actieve component van het vaccin is het 
manteleiwit van het virus, het hepatitis B oppervlakte antigen of HBsAg. Anti-lichamen gericht tegen het HBsAg-vaccin volstaan 
immers om de infectie die kan volgen op de blootstelling aan het HBV te voorkomen. Jammergenoeg blijken ongeveer 5 à 10% van de 
gezonde gevaccineerden niet in staat om een beschermende antilichaamtiter te produceren na een standaard hepatitis B immunisatie. 
Deze 'HBsAg nonresponders' zijn waarschijnlijk niet of onvoldoende beschermd. Het mechanisme verantwoordelijk voor deze 
gebrekkige immuunrespons tegen het HBsAg is niet bekend. Via een grondige analyse van de humane cellulaire reactie tegen HBsAg 
bij HBsAg-gevaccineerden wensen wij het mechanisme verantwoordelijk voor deze 'HBsAg nonresponsiveness' op te helderen. Deze 
kennis zou kunnen bijdragen tot de ontwikkeling van een nieuw, meer immunogeen vaccin dat bij iedere gevaccineerde een 
beschermende antilichaamtiter kan opwekken. Daar de afwezigheid van een immunologische reactie tegen de HBV manteleiwitten ook 
gezien wordt bij chronische dragers van het HBV, kan een grondige kennis van de humane immuunreacties tegenover het HBsAg ook 
heel nuttig zijn om ons te helpen begrijpen waarom chronische dragers er niet in slagen het virus te elimineren. Deze kennis kan, op 
langere termijn, eventueel leiden tot de ontwikkeling van een adequate therapie voor de behandeling van chronische infecties. Wij 
denken hierbij in de eerste plaats aan de ontwikkeling van een therapeutisch vaccin. 
Deel 1: Relatie tussen HLA en 'nonresponsiveness'. Variaties in het immuunantwoord zijn vaak geassocieerd met polymorfismen van 
het MHC (Major Histocompatibility Complex). Het frequenter voorkomen van 'HBsAg-nonresponsiveness' bij personen met een 
HLA-DR3 of -DR7 haplotype suggereert dat deze nonrespons gestuurd wordt door genen van het MHC. In dit proefschrift worden 
HLA merkers van goede (DR1,DR5,DP4,DQ3 en DQ5) en van zwakke (DR7,DP11 en DQ2) respons geïdentificeerd. Vooral de 
combinaties DR3~DR7 en DP2~DR7 bleken frequent voor te komen in de nonresponder populatie. 
Deel 2: Exploratie van de antigenpresentatie bij 'nonresponders'. Het immunologisch defect verantwoordelijk voor de 'HBsAg 
nonresponsiveness' kan op elk niveau van het humaan immuunantwoord liggen. In dit proefschrift wordt nagegaan of een defect in 
HBsAg-opname, -processing of -presentatie verantwoordelijk is voor de gebrekkige of afwezige anti-HBs productie bij nonresponders. 
Door middel van een functionele analyse toonden we aan dat het opname-, processing- en presentatiegebeuren correct verloopt bij deze 
personen. 
Deel 3: Identificatie van HBsAg-specifieke T helper epitopen. Recent onderzoek toonde aan dat bij gevaccineerden de sterkte van de 
humorale immuunrespons op HBsAg grotendeels bepaald wordt door de kwaliteit van het T cel antwoord op dit antigen. Er werd 
immers een duidelijke correlatie gevonden tussen de in vivo anti-HBs productie en de in vitro T cel proliferatie. Om beter te begrijpen 
hoe HBsAg door T cellen wordt herkend, werden een aantal HBsAg-specifieke T cellijnen geproduceerd waarvan de epitoop-
herkenning en HLA-restrictie werden bepaald. Bovendien werden, gebruik makend van lymfocyten uit het perifeer bloed van goede 
HBsAg-responders en van een reeks peptiden die 60% van de HBsAg sequentie omvatten, enkele dominante T cel epitopen van 
HBsAg geïdentificeerd. 
Deel 4: Zoektocht naar verbeterde hepatitis B vaccins. Met het oog op de ontwikkeling van een meer immunogeen hepatitis B vaccin 
werden de veiligheid en de immunogeniciteit van een experimenteel hepatitis B vaccin (HBsAg met preS1 en preS2 sequenties) 
geanalyseerd in gezonde adolescenten en in nonresponders op het klassieke vaccin. Noch de gezonde adolescenten, noch de 
nonresponders op het klassieke vaccin reageerden beter op het experimenteel vaccin dan op het controle vaccin (Engerix-B®). Deze 
klinische evaluaties toonden aan dat de geselecteerde preS1 en preS2 gebieden de immunogeniciteit van het HBsAg-vaccin niet 
verbeterden. In een reeks in vitro experimenten werd aangetoond dat gedelipideerd HBsAg een verhoogde immunogeniciteit heeft 
vergeleken met het natief HBsAg. Ontvetting van HBsAg leidt tot een betere herkenning door T lymfocyten. De ontvetting resulteert 
evenwel in een minder goede herkenning van HBsAg door B lymfocyten en als gevolg daarvan in een geringere productie van anti-
HBs. 
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I.2. Summary 
Prevention of hepatitis B virus (HBV)-infection through vaccination has been routinely practiced for more than 15 years. The active 
compound of the vaccine is the envelope protein of HBV, the hepatitis B surface antigen or HBsAg. Antibodies to the HBsAg-vaccine 
have been shown to be effective in preventing infection after exposure to this agent. However, approximately 5 to 10% of healthy 
vaccine recipients fail to produce protective levels of antibodies to the hepatitis B vaccine after standard immunization. These HBsAg 
nonresponders may therefore be not or only inadequately protected. The mechanism responsible for this deficient immune response 
against HBsAg is unknown. By analyzing the human cellular reaction to HBsAg in HBsAg vaccinees we wish to unravel the 
mechanism responsible for HBsAg nonresponsiveness. This knowledge can be useful for the development of a new, more 
immunogenic vaccine that induces a protective anti-HBs response in all vaccinated individuals. Since a defective HBsAg 
responsiveness is also observed in chronic carriers of the HBV, new insights in human immune response to HBsAg, can help to 
understand why chronic carriers are unable to clear the virus. In the long run this knowledge may lead to the development of an 
adequate therapy to cure patients suffering from a chronic HBV infection. The development of a therapeutic vaccine may be one of the 
strategies to consider.   
Part 1: HLA and 'HBsAg-nonresponsiveness'. Variations in the strength of the immune response are often associated with 
polymorphisms of the MHC (Major Histocompatibility Complex). The higher incidence of HBsAg-nonresponsiveness in individuals 
with a HLA-DR3 or -DR7 haplotype suggests that genes of the MHC are involved. In this thesis we identified HLA-markers of good 
(DR1,DR5,DP4,DQ3 and DQ5) and of poor (DR7,DP11 and DQ2) response. Especially the combinations DR3~DR7 and DP2~DR7 
occur more frequently in the nonresponder population. 
Part 2: Immune defect responsible for 'HBsAg-nonresponsiveness'. The immunological defect responsible for HBsAg 
nonresponsiveness may reside in each of the different steps of the human immune response. In this thesis we analysed whether a defect 
in HBsAg-uptake, -processing or -presentation is responsible for the inadequate or absent anti-HBs production in nonresponders. This 
functional analysis demonstrated that the processing and presentation phases are not deficient in these individuals.   
Part 3: Identification of HBsAg-derived T helper epitopes. Recent research demonstrated that, in vaccinated individuals, the magnitude 
of the humoral immune response towards HBsAg is largely determined by the quality of the T cell response towards this antigen. A 
strong correlation between the in vivo anti-HBs production and the in vitro T cell proliferation was demonstrated. To better understand 
how T cells recognize the HBsAg, we generated a series of HBsAg-specific T cell lines and determined their epitope- and HLA-
restriction. Furthermore, by using peripheral blood lymphocytes of good responders and a panel of overlapping synthetic peptides 
spanning 60% of the HBsAg sequence, we identified several dominant T cell epitopes. 
Part 4: In search of more immunogenic HBsAg-vaccines. In the scope of the development of a more immunogenic hepatitis B vaccine, 
we analysed the safety and immunogenicity of an experimental hepatitis B vaccine (HBsAg with preS1 and preS2 sequences) in a 
cohort of healthy young adults and in nonresponders to the classic vaccine. These clinical evaluations demonstrated that the selected 
preS1 and preS2 regions do not improve the immunogenicity of the S-vaccine. Nor the healthy adults, nor the nonresponders to the 
classic vaccine reacted better to the experimental vaccine than to the control vaccine (Engerix-B®). A series of in vitro experiments 
revealed that delipidated HBsAg is more immunogenic as compared to the native HBsAg. The delipidated HBsAg is better recognized 
by T lymphocytes than the native HBsAg. However, delipidation of HBsAg reduced its B cell immunogenicity, and thus lowered the 
anti-HBs antibody production. 
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I.3. Résumé 
La vaccination routinière contre l'hépatite B (HBV) se pratique depuis plus de 15 ans. Puisque les anticorps générés par l'antigène de 
surface de l'hépatite B (HBsAg) se sont montrés effectifs dans la prévention de l'infection après exposition au HBV, la partie active 
du vaccin contre l'hépatite B est composée de ces HBsAg (= des protéines de l'enveloppe du virus). Malheureusement, 5 à 10% des 
vaccinés en bonne santé sont incapables de produire des taux d'anticorps protectifs après une vaccination normale (standard). On 
assume que ces 'nonrépondeurs à l'HBsAg' ne sont probablement pas - ou seulement partiellement - protégés. Par le biais d'une étude 
approfondie de la réaction cellulaire humaine envers l'HBsAg auprès des personnes vaccinées à l'HBsAg, nous souhaitons éclaircir le 
mécanisme qui est responsable pour la 'nonréponse à l'HBsAg'. Cette connaissance pourrait être appliquée au développement d'un 
nouveau vaccin plus immunogène qui pourrait induire chez toutes les personnes vaccinées un taux d'anticorps protectifs. En outre on 
retrouve une même déficience de réponse immunologique chez les personnes atteintes d'une infection chronique d'hépatite B et par 
conséquent porteurs du virus de l'HBV. Une meilleure connaissance des réactions immunologiques humaines envers l'HBsAg 
pourrait nous aider à mieux comprendre pourquoi ces malades chroniques ne parviennent pas à éliminer le virus. Par conséquent on 
pourrait imaginer, dans le futur, de développer une thérapie adéquate, par exemple par le développement d'un vaccin thérapeutique.     
1ère Partie: Relation entre 'HLA (human leucocyte antigen)' et nonréponse. Les variations en réponse immunologique sont souvent 
associées aux polymorfismes du CMH (Complex Majeur d'Histocompatibilité). La nonréponse à l'HBsAg se manifeste plus 
fréquemment chez des personnes portant l'haplotype HLA-DR3 ou -DR7. Ceci suggère que cette nonréponse est dirigée par des gènes 
du CMH. Dans cette thèse nous avons pu identifier des marqueurs HLA (DR1,DR5,DP4,DQ3 et DQ5) associés à une bonne réponse 
et des marqueurs HLA (DR7,DP11 et DQ2) associés à une faible réponse. Nous démontrons qu'en particulier la combinaison DR3-
DR7 et la combinaison DP2-DR7 se retrouvent plus fréquemment dans la population des nonrépondeurs. 
2ème Partie: Exploration de la présentation de l'HBsAg chez les nonrépondeurs. La déficience immunologique responsable pour la 
nonréponse à l'HBsAg peut se situer à chaque niveau de la réponse immunologique humaine. Dans cette thèse, nous analysons 
l'hypothèse que chez les nonrépondeurs, un défaut à hauteur de la prise, de la décomposition ou de la présentation de l'HBsAg est 
responsable d'une absence ou d'un taux trop faible d'anticorps anti-HBs. Par analyse fonctionnelle nous démontrons que ces processus 
se déroulent d'une façon normale chez ces personnes.     
3ème Partie: Identification d'épitopes T spécifiques envers l'HBsAg. Récemment il a été établi que l'ampleur de la réponse humorale 
envers HBsAg est en majeure partie déterminée par la qualité de la réponse des lymphocytes T envers cet antigène chez des 
personnes vaccinées. Il a été démontré qu'il existe une relation entre la production d'anticorps in vivo et la prolifération des 
lymphocytes T in vitro. Pour mieux comprendre comment les lymphocytes T reconnaissent l'HBsAg, nous avons généré une série de 
lignes de lymphocytes T spécifiques envers l'HBsAg. La reconnaissance de l'épitope et la réstriction HLA de ces lignes ont été 
déterminées. En plus, des épitopes T dominants ont été définis en utilisant des leucocytes provenant de bons répondeurs HBsAg et de 
peptides synthétiques couvrant 60% de la séquence HBsAg. 
4ème Partie: Recherche d'un vaccin hépatite B amélioré. En vue du développement d'un vaccin plus immunogène contre l'hépatite B 
nous avons analysé la sécurité et l'immunogénicité d'un vaccin expérimental (HBsAg avec en addition des séquences du preS1 et du 
preS2). Ces études de vaccination ont été faites chez des adolescents en bonne santé et chez des nonrépondeurs envers le vaccin 
classique. Nous n'avons pas pu trouver une meilleure réponse envers le vaccin expérimental comparé au vaccin de contrôle classique 
(Engerix-B®). En conclusion, les évaluations cliniques ont démontré que les séquences sélectées (preS1 et preS2) n'amélioraient pas 
l'immunogénicité du vaccin HBsAg. Dans d'autres expériences in vitro nous avons démontré que les particules d'HBsAg délipidées 
ont un plus grand pouvoir immunogène que les particules natives. Une délipidation de l'HBsAg provoque une meilleure 
reconnaissance des lymphocytes T. Par contre, nous avons constaté une production moindre d'anticorps anti-HBs, ce qui nous permet 
de supposer que la délipidation de l'antigène cause une moindre reconnaissance par les lymphocytes B. 
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II. Introduction 
II.1. General introduction 
Hepatitis is a general term for an inflammation of the liver due to a variety of causes including metabolic 
diseases, drugs, alcohol, toxins, and viruses. Viruses are the most common causative agents of hepatitis today 
and infect many millions of individuals annually. Viral hepatitis encompasses several diseases and represents a 
global health problem. It induces major morbidity and mortality and places enormous demands on economic 
and medical resources. Several viruses that cause hepatitis have been isolated in the past decades: hepatitis A 
(formerly 'infectious' hepatitis), hepatitis B ( formerly 'serum' hepatitis), hepatitis C (formerly 'non-A, non-B' 
hepatitis), hepatitis D (delta hepatitis), and hepatitis E (formerly 'enterically transmitted non-A, non-B' 
hepatitis). The 'hepatitis F virus', once classified as a hepatitis causing agent, was shown to be a mistake. 
Recently, a new virus (hepatitis G or GBV-C) has been identified as a sixth viral agent. It is possible that other 
viruses associated with hepatitis will be identified in the coming years [1,2].  
 The hepatitis B virus (HBV) is a major cause of infectious liver disease. Worldwide approximately 300 
million people are persistent carriers of HBV. In East Asia and tropical Africa, where vertical transmission of 
HBV is the major cause of infection, more than 10 per cent of the population are chronic carriers (Figure 1). 
Chronically infected patients with active liver disease carry a high risk of developing cirrhosis and hepatocellu-
lar carcinoma (HCC). In fact, the risk of HCC is 100-fold in patients with chronic HBV infection [3]. The 
latency period between infection and cancer varies from 35 to 45 years and liver cancer is seen mostly in those 
parts of the world where childhood or perinatal infection is common. Most primary liver cancers (60% to 70%) 
globally occur in HBV carriers, and an estimated one million deaths from HBV related liver cancer occur 
annually. HBV-related primary hepatocellular carcinoma is one of the major causes of cancer-related death in 
major parts of Africa, Asia and Latin-America.   
 The clinical consequences of HBV infection are extremely variable and unpredictable. The virus can cause a 
disease of variable duration and severity, ranging from a subclinical form to acute hepatitis and severe chronic 
liver disease. After clinically apparent acute hepatitis B infection, approximately 90% of affected adults recover 
without sequelae, and develop lifelong immunity to the virus. In another 0.1-0.5% of cases a fulminant hepatitis 
results in which hepatocellular damage is so extensive that fewer than 50% of the patients survive. Finally, 5-
10% of adults exposed to HBV are unable to eliminate the virus and develop a chronic infection. The nature of 
the chronic infection is also variable, ranging from continuous hepatocellular necrosis and inflammation 
(chronic active hepatitis) to an asymptomatic carrier state. In contrast to adult infection, neonatal HBV infection 
is rarely cleared and as many as 90% of perinatally infected children become chronically infected [4]. 
 Until now, the mechanism of liver damage in HBV infection is not fully understood. Asymptomatic HBV 
carriers can have relatively normal liver morphology and function despite the presence of high levels of viral 
replication within their hepatocytes. This and a number of other observations have led investigators to the 
conclusion that liver injury and the subsequent clearance of virus during HBV infection is mediated by the 
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immune response, and that the HBV is not directly cytopathic [5]. Clearly, both arms of the immune response 
are involved in viral clearance. While the cellular immune response to the envelope, nucleocapsid, and 
polymerase antigens eliminates infected cells, the humoral antibody response to the hepatitis B surface antigen 
(HBsAg) contributes to the clearance and elimination of circulating virus particles after acute infection. This 
implies that an inadequate immune response leads to chronicity. Anti-HBs was clearly shown to be the serologic 
marker indicating the start of recovery in infected individuals and is the protective mechanism against re-infec-
tion in convalescent patients. Among other deficient immune responses, an inadequate cellular and humoral 
anti-HBs immune response has been observed in chronically infected patients, with no detectable anti-HBs in 
their serum. Immune unresponsiveness to HBsAg is thus considered to be a contributing factor in the 
pathogenesis of the persistent infection [6]. 
 Since 1981 HBsAg-vaccination against HBV infections has been routinely practiced and antibodies to the 
HBsAg have been shown to be effective in preventing infection after exposure to this agent. Several studies 
have shown that these vaccines are safe, well-tolerated and effective. Since the current therapies for chronic 
HBV infection, such as IFNα, antiviral drugs and liver transplantation, are very expensive, have numerous and 
often serious side effects, and are, at best, only partially successful, active immunoprophylaxis (HB vaccination) 
seems to be the best way to cope with the problem of chronic hepatitis B. It is anticipated that effective HBV 
vaccine programs will interrupt the vicious cycle of perinatal infection, chronicity and late term complications 
including HCC. Until now, the increasing and systematic administration of vaccines slowly causes a decline in 
HBV incidence in both non-endemic and some endemic areas. Still, major impediments for the total eradication 
of HBV and its associated pathologies exist. Firstly, there is a non-negligible degree of nonresponsiveness 
following hepatitis B vaccination. Five to 10 percent of healthy young adults, 40% of hemodialysis patients, 
25% of intravenous drug users and up to 90% of patients under immunosuppresive therapy display an 
inadequate antibody response (<10 IU/L) following a standard vaccination schedule with HBsAg vaccine. 
These non/poor-responders are not or inadequately protected against primary infection [7]. Secondly, there is 
the high frequency of chronicity following primary infection. These individuals are unable to clear the virus and 
form a permanent reservoir for the HBV.   
 Both groups, vaccinees as well as chronic carriers, are characterised by a deficient immune response to 
HBsAg. Until now, the mechanisms responsible for this HBsAg-nonresponsiveness, in vaccinees as well as in 
chronic carriers, remain largely unknown. However, the diversity of clinical syndromes induced by an HBV 
infection (acute versus chronic infection,...) and the variability of the humoral immune response to HBsAg after 
vaccination (high versus non/low responders) suggest a genetic regulation of the immune response to HBsAg in 
man, as was demonstrated in mice [8].   
 Whether the mechanism responsible for this immune deficiency is the same in both groups remains to be 
elucidated. In this thesis we tried to answer this question by unravelling the mechanism responsible for the 
immunological nonresponsiveness to HBsAg in vaccinees. By analyzing HBsAg-presentation, B7-
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costimulation and HLA-linkage in hepatitis B vaccine nonresponders we were able to exclude some of the 
hypothetical mechanisms that could lead to this deficiency.  
 Since vaccination is the only route for eradication of HBV, development and delivery of a vaccine which is 
effective against all strains, and which induces a response in all vaccine recipients without exceptions, is an 
absolute requirement. The occurrence of nonresponsiveness and the reports of breakthrough infections 
following vaccination, due to the emergence of escape mutants with variant HBsAg sequences are signals to 
reconsider vaccine design [9]. By analyzing the genetic and cellular (especially the identification of dominant T 
cell epitopes) factors controlling the quality of the immune response to HBsAg and by modifying the HBsAg-
vaccine, we hope to have contributed to the development of a more immunogenic HBsAg-vaccine.  
 The elucidation of the mechanism(s) responsible for the immunological nonresponsiveness to HBsAg and 
the development of a more immunogenic HBsAg-vaccine to induce an adequate immune response in all vaccine 
recipients, irrespective of the vaccination being prophylactic or therapeutic, are indispensible to combat HBV in 
the community and are, by consequence, the long-term objectives of this study.  
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II.2. Structural proteins of the hepatitis B virus 
HBV is the prototype agent for a virus family called hepadnaviridae (hepatitis associated DNA viruses). All 
hepadnaviruses have a moderately narrow host range. HBV infects higher primates including men, chimpanzees 
and gibbons. Other monkeys are normally not infected. This limited host range of HBV and the lack of avai-
lable in vivo and in vitro models, hindered the initial studies on HBV. The discovery of other hepadnaviruses 
has led to the development of alternative systems for studying the infection, replication and pathogenesis of 
HBV. Other members of the hepadnaviridae include WHV (woodchuck hepatitis virus), GSHV (ground squirrel 
hepatitis virus), TSHV (tree squirrel hepatitis virus), DHBV (duck hepatitis B virus), and the HHBV (heron 
hepatitis B virus). These viruses share the same structural and biologic characteristics, but have another host cell 
specificity. They all have small circular DNA molecules that are partly single stranded and an endogenous poly-
merase that repairs the DNA to make it fully double stranded. Species specificity (narrow host range), liver 
tropism (targetting of the virus to the hepatocytes), and the development of persistent infection further cha-
racterize this group. Although hepadnavirus infections have in the past been considered to be strictly hepatotro-
pic, viral DNA, RNA and antigens have now also been detected in non-hepatocytes, including bile duct epithe-
lial cells and endothelial cells in the liver, pancreas, kidney, adrenal cortex, skin, Kaposi sarcoma, spermatozoa, 
placenta, macrophages, spleen, bone marrow and a variety of peripheral white blood cells. It was demonstrated 
that once viral DNA has been internalized, most cell types are permissive, at least to some extent, for viral gene 
expression and DNA replication. Still, high-level viral gene expression and replication are only observed in the 
liver [11-14].  
 The hepatitis B genome (Figure 2) consists of a small, circular DNA molecule that is partially double-
stranded. The DNA is composed of a long strand with a constant length (3182 bases) and a short strand which 
varies in length between 1700 and 2800 bases. The long strand carries virtually all the protein coding capacity 
of the virus and can therefore be considered as the minus strand. The short strand, devoid of coding function, is 
the plus strand. The circular structure of the DNA is maintained via baseparing at the 5' end of the 2 strands. 
This region contains identical direct repeat sequences of 11 to 12 nucleotides, designated DR1 and DR2. The 
direct repeat sequences are involved in the priming of plus and minus strand DNA, and the terminal redundancy 
is important for plus strand transfer and formation of the circular genome. In spite of their small genome size, 
hepadnaviruses are able to produce a remarkable variety of proteins. This is achieved through a combination of 
overlapping open reading frames (ORFs) and different start sites for translation to produce multiple related 
products from a single ORF with varying amino-terminal additions. The HBV genome contains four ORFs: the 
C-, the P-, the S-, and the X-ORF. The S region codes for the proteins of the viral envelope and is devided into 
the S gene, preS1 region and preS2 region. The C gene encodes the core protein and the P region encodes the 
viral DNA polymerase which possesses reverse transcriptase activity. The hepatitis B virus X protein (HBxAg) 
is a promiscuous transcriptional activator of polymerase II and III promotors, and up-regulates a wide range of 
cellular and viral genes. The function of HBx in viral replication and life cycle is still not completely elucidated. 
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The surface antigen ORF entirely overlaps with the P ORF [11,14-16]. 
 Mature hepatitis B virions (Figure 3), also known as Dane particles, are surrounded by an outer membrane 
layer, the envelope, into which are inserted three related forms of a virally encoded transmembrane protein, the 
surface antigen. The lipids of this lipoprotein coat (fosfolipids, cholesterol and triglycerids) are derived from the 
host. The envelope encloses the nucleocapsid, an icosahedral structure formed by the viral core protein. The 
nucleocapsid contains the relaxed circular DNA genome, including the terminal protein covalently bound to the 
5' end of the minus strand DNA, and the viral polymerase [17].  
 During HBV infection, at least four antigen-antibody systems are observed: hepatitis B surface antigen 
(HBsAg) and its antibody (anti-HBs); the preS antigens associated with HBsAg particles and their antibodies; 
the particulate nucleocapsid antigen (HBcAg) and anti-HBc; and an antigen structurally related to HBcAg, 
namely, HBeAg and its antibody (anti-HBe) (Figure 4). Antibodies are also produced to the non-structural 
polymerase [19,20] and X [21,22] proteins, primarily during chronic infections. The specific serologic marker 
of HBV infection is HBsAg, which is present both in the intact virion (42 nm diameter, infectious) and as 
excess free circulating filamentous (not infectious, different lengths, 22 nm diameter) and spherical 22 nm 
subviral particles (not infectious). These subviral particles can achieve concentrations approaching 100 µg/ml in 
the sera of chronic HBV carriers, and served as the source of the original plasma-derived HBsAg vaccines. 
Experience with HBV vaccination has taught that antibodies to HBsAg (major protein) are protective against 
HBV infections [23]. 
 Three different forms of the HBsAg, termed the small (S), middle (M), and large (L) surface proteins (Figure 
4-5). These are produced from a single ORF with three distinct translational start sites and one stopcodon. This 
explains why the 226 carboxyterminal AA of the three envelope proteins are identical. The smallest protein, 
called the major, S or small hepatitis B surface antigen (SHBsAg), is 226 AA long and is quantitatively the most 
important component in the empty virus particles as well as in the intact virions. The second envelope protein of 
HBV, called middle envelope protein (MHBsAg), is identical to the HBsAg, but has an amino-terminal 
extension of 55 AA, termed the preS2 sequence. The third envelope protein, called the large envelope protein 
(LHBsAg), is similar to the M protein, but is elongated at its amino-terminus with 120 AA, termed the preS1 
sequence. The three envelope proteins can be glycosylated and, depending on the degree of glycosylation, SDS 
gel electrophoresis of purified particles shows three pairs of proteins or glycoproteins, respectively: P24 and 
GP27 for SHBsAg, GP33 and GP36 for MHBsAg, P39 and GP42 for LHBsAg. The larger protein of the pairs 
is the N-glycosylated form of the smaller one. There are two glycosylation sites, N146 of the S protein and N4 
of the M protein. N4 is always glycosylated in secreted particles and N146 is only partially glycosylated when 
the S domain is part of the M and L proteins. S protein contains all the elements required for its own folding and 
can self-assemble, forming an aggregate of 60-120 transmembrane S monomers in host-derived lipids. These 
particles, produced either by recombinant means or purified from serum of infected subjects, are the basis of the 
current vaccines. It appears that a high proportion of LHBsAg is required for the maturation of HBV and for the 
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secretion of HBsAg filaments. The surface antigen proteins are cotranslationally inserted into the membrane of 
the ER. The envelope proteins have the ability to assemble into 22 nm spheres and filaments that bud into the 
lumen of the ER and the Golgi compartment. This auto-assembly process results in the production of a large 
excess of subviral particles compared to virions in the serum of viraemic individuals [24].  
 The spatial structure of the hepatitis B envelope proteins is incompletely understood but computer analysis 
of topogenic elements and mutational approaches have provided a model of the organization of the HBsAg 
protein [25,26](Figure 6a). Most current models for the transmembrane structure of S assume an external 
disposition of both the N- and C-termini, and four hydrophobic and two hydrophilic domains. Although four 
transmembrane α-helices are predicted, only the two most N-terminal domains are important for correctly 
anchoring the S protein to the membrane [27]. These two domains, corresponding to amino acids 11-28 and 80-
98 respectively, are spaced by a hydrophilic region exposed on the internal side of the mature particle. This first 
hydrophilic region may thus be involved in attachment and development of the core particle during maturation 
of the virion. Deletion mutants reveal that this region tolerates only minor structural changes; three of the four 
cysteine residues in this region are conserved amongst all hepadnaviruses and were shown to be essential for 
secretion [28]. The second hydrophilic loop (amino acids 99-168) is exposed on the outer virion/particle surface 
since it contains the major group- and subtype-specific antigenic determinants and acquires carbohydrate 
modification. It is still unclear whether this region is directly involved in hepatocyte binding. 
 Receptor binding is probably a multi-step process involving several regions of HBV envelope proteins and 
including attachment of regions of the S protein, possibly to annexin V on the surface of the liver cell [29,30]. 
The external hydrophilic region has a highly complex structure and is very cysteine-dense: eight of the 14 
cysteine residues in HBsAg are located here, and all eight are highly conserved among mammalian 
hepadnaviruses and HBV subtypes. There is, therefore, the potential for a high degree of secondary, tertiary and 
quaternary structure through the formation of intra- and inter-molecular disulphide bridges. Antigenicity is 
dependent upon this complex structure and substitution of many of the cysteine residues results in loss of 
immunoreactivity. However, not all cysteines are equally important for antigenicity and/or secretion [31]. The 
general role of cysteines in maintaining HBsAg conformation is well established, however, the exact structure 
of this region is unsolved. Structural predictions, use of cyclical peptides and phage library screening with 
monoclonal antibodies all provide stronger evidence for clusters of epitopes and a more complex structure [32]. 
The greatest affinity of anti-HBs is for epitopes in the second loop, antigenicity of which depends on key 
residues at AA 141-146 (KPTDGN). This has been studied using peptides in amino acid replacement assays 
[33] and by mutagenesis of yeast expressed HBsAg [34]. The major B cell epitope cluster of S protein is widely 
and historically referred to as the 'a' determinant. Many data have indicated that this spanned AA 124 to AA 
147, but recent evidence suggests that this epitope cluster could be extended up- and downstream to include the 
entire major hydrophilic region (MHR). Although one would imagine the MHR to be a rigid structure, Wallace 
and Carman [9] hypothesize it to be a fluid structure where key antigenic regions are held in place by intra- and 
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inter-molecular bridging (Figure 6b). Some mAbs recognized epitopes that were up to 70 residues apart, which 
probably become spatially close when the molecule folds; alternatively, some epitopes may be contributed from 
adjacent S molecules. However, the exact fine structure of this region remains unresolved. 
  The hepatitis B virus surface protein has a degree of natural variation which is linked to ethnic and 
geographical backgrounds. This natural variability has evolved and become stable over the millenia. The 
serologic heterogeneity of the HBV has been established from immunodiffusion experiments for a long time. 
Four serotypes of HBsAg have been defined by two mutually exclusive determinant pairs, 'd/y' and 'w/r', and the 
common group-specific 'a' determinant. Therefore, the four subtypes of HBsAg (adw, ayw, adr, and ayr) 
represent the major viral phenotypes. By subdivision of the four major subtypes, nine different subtypes were 
identified. It was observed early that the ayw subtype was the one found among drug addicts worldwide, that 
the adw subtype dominated among the carriers in northwestern Europe, and that the subtypes with the 'r' 
determinant were exclusively confined to populations of the Far East [35].  
 A genetic classification based on the comparison of complete genomes has defined six genotypes of HBV, 
named A to F, defined by an 8% (up to 14% in genotype F) difference in sequence across the whole genome. 
Genotypes A to F are associated with distinct geographical areas. In addition there are nine subtypes, defined by 
a 4% difference in S gene sequence. By sequencing the S gene of HBV the molecular basis was assessed for the 
serological variations of HBsAg within the major four subtypes. However, the interrelation of the nine subtypes 
to the genotypes, the possible presence of more HBV genotypes as well as their global geographical prevalence 
remained to be determined. Variant HBsAg sequences have been detected worldwide and these appear to be 
antigenically relevant. There are two classes of variants: class 1 variants are found naturally and class 2 variants 
are observed in individuals that underwent a medical intervention (passive or active immunisation or antiviral 
therapy). Naturally occurring variants (reviewed in [36]) are usually not clinically significant, but there are 
examples which affect diagnostic assays. Class 2 variants, also referred to as mutants, are discussed in section 
II.5.8.  
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II.3. Hepatitis B virus and chronic hepatitis 
HBV is a viral disease of global dimension with more than 300 million carriers of the virus worldwide. In coun-
tries where HBV carrier rates reach 10%, HBV infection may account for 3% of total mortality. The route of 
transmission varies geographically and is associated with the prevalence of HBV infection in this area. In areas 
of low HBV endemicity (Figure 7), infection occurs primarily in adolescents and adults and is transmitted 
sexually or parenterally. In areas of intermediate prevalence (carrier rate of 2-7%), HBV is spread horizontally, 
with the highest rate of infection occurring among older children, adolescents and adults. In areas with a high 
HBV prevalence (carrier rate of 8-20%), infection occurs primarily among infants and children through mother-
child transmission (perinatal) and through close personal contact among children (horizontal). Although 
endemicity rates in Africa and south-east Asia are comparable, horizontal transmission predominates in Africa 
and vertical, perinatal transmission predominates in south-east Asia. The reason for this phenomenon is 
unknown, but this difference may in part be due to the higher prevalence of HBeAg in Asian (40%) than Afri-
can (15%) mothers [38].  
 HBV chronic carriers represent a permanent viral reservoir, which hampers the total eradication of HBV and 
its associated pathologies. The diagnosis of chronic hepatitis B is established when transaminases (ALT/AST) 
are elevated and HBsAg is peristently present in serum for a period of at least six months. These patients are 
characterized serologically by the absence of anti-HBs, antibodies found in most individuals who have 
recovered from acute infection [39]. 
 Chronic sequelae of HBV infection include chronic hepatitis (CH), liver cirrhosis and hepatocellular 
carcinoma (HCC)[40]. Epidemiologic studies and laboratory experiments showed that HBV is one of the most 
important etiologic factors of HCC, one of the most common cancers worldwide [41,42]. Primary hepatocellular 
carcinoma (PHC), induced by an HBV infection, is one of the most frequently encountered causes of death in 
major parts of Africa, Asia and South America [43,44]. CH has two forms: persistent (CPH) or active (CAH) 
depending upon the extent of portal triad disruption. In the Far East CAH is most often a mild or subclinical 
disease. Liver biopsy shows evidence of piecemeal necrosis with or without cirrhosis [45]. 
 There is usually an inverse relationship between the levels of virus replication and liver inflammation. High 
levels of virus replication are associated with low inflammatory activity (CPH), reflecting the host tolerance and 
the immunological unresponsiveness to the virus. On the contrary, histological findings of CAH are usually 
associated with low levels of virus replication. The severity of the inflammatory changes reflects the intensity of 
the immunological response and the efficiency of virus clearance. These and other observations tend to indicate 
that chronic hepatitis B is not caused by a direct cytopathic effect of the HBV virus but by the host's immune 
response [5,46]. 
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II.4. HBsAg recognition by the immune system 
II.4.1. T cell recognition of antigen and MHC gene products: general properties. 
An adequate immune response can only ensue when T lymphocytes recognize foreign antigenic fragments. T 
cells do not bind protein antigens directly, but recognize a heteromolecular complex consisting of a major 
histocompatibility complex (MHC) molecule and a peptide fragment of a protein antigen. The binding capa-
bility of the peptide-fragment to the MHC molecule depends on the primary sequence of the peptide and on 
allelic variation of the residues in the binding site of the MHC receptor [47,48]. HLA, the MHC of humans, is 
an assembly of closely linked genes of chromosome 6. The most remarkable characteristic of HLA genes 
(polygenic) is their genetic variability or polymorphism. Most of the genes are highly polymorphic, and many 
variants or alleles can be distinguished. The HLA gene products are codominant since each individual expresses 
two antigens per locus. An individual can be either homozygous (expression of 2 identical alleles) or hetero-
zygous (expression of 2 different alleles) for a locus. Since HLA loci comprising the haplotype are closely 
linked, they are inherited as a genetic unit. Each individual, therefore, has two HLA haplotypes, one contributed 
by each parent. Based on their structure and function, HLA molecules can be divided in 2 major categories: 
'HLA-class I' and 'HLA-class II' molecules (Figure 8). Both classes consist of cell surface glycoproteins. The 
HLA class I molecules, assigned as the HLA-A, HLA-B and HLA-C series, are present on the membranes of 
most nucleated cells. They are composed of a HLA-encoded α-chain with a MW of 45000, which is associated 
non-covalently, with a smaller beta chain of 11 kilodaltons. This smaller chain corresponds to the ß2- 
microglobulin found in serum and urine and is encoded by chromosome 15. The heavy chain, which is very 
polymorphic, has three extracellular domains each consisting of about 90 AA. The HLA class II antigens are 
less polymorphic, have a more restricted distribution than the class I antigens, but have a more complex genetic 
and structural composition. They are mainly expressed on B cells, activated T cells, antigen-presenting cells 
(monocytes, macrophages and dendritic cells), and thymic epithelium. The three most important HLA class II 
molecules (HLA-DR, -DP, and -DQ) are heterodimers consisting of an α- and a ß-chain. Both HLA-encoded, 
non-covalently associated chains are inserted through the cell membrane via hydrophobic regions. The respec-
tive molecular weights are 33000 (heavy or α-chain) and 27000 (light or ß-chain). The HLA-DR locus can 
encode for one α- and three ß-chain genes. One gene coding for the DRα-chain, DRA, and one gene coding for 
the ß-chain, DRB1, is always present. Depending on the DR type, a DRB3, DRB4, or DRB5 gene may be pre-
sent as well, eventually accompanied by pseudogenes. So, the HLA can express 1 or 2 HLA-DR molecules. The 
first DR molecule, encoded by the DRA (α-chain) and DRB1 (ß-chain) loci, is always expressed. The possible 
second DR molecule is encoded by the DRA and the DRB3, DRB4 or DRB5 loci. The DRB1 gene is the most 
polymorphic of the human class II genes with over 120 alleles identified, making it a powerful marker for 
individual identification. DRA is not polymorphic (only 2 alleles have been described) and some polymorphism 
is described in DRB3, DRB4, and DRB5. All these genes consist of 7 exons. Most of the allelic polymorphisms 
are located in exon 2, encoding the amino-terminal extracellular domain which functions as the antigen binding 
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site for processed proteins.    
 The HLA-DQ and HLA-DP loci each encode for two α- and two ß-chain genes. However, both the HLA-
DQ and -DP regions only contain one functional gene each for the α- and the ß-chain. HLA-DQ molecules are 
encoded by the DQA1 and DQB1 loci. Both components are polymorphic, and both are thought to contribute to 
specificity. HLA-DP molecules are encoded by the DPA1 and DPB1 loci, both contributing to polymorphism 
[49]. 
 The HLA alleles were designated by a consensus nomenclature adapted by the World Health Organization. 
Each year an update with newly assigned sequences, confirmations or corrections of previously reported 
sequences is published. Each HLA locus as it is defined, is assigned a letter in alphabetical order, e.g. HLA-A, 
HLA-B, etc. Universally accepted specificities are designated by Arabic numerals, such as HLA-A1, HLA-B5, 
HLA-DR3, etc. DRB1*XXXX refers to the genetic HLA typing. It was agreed that serologically identified 
products of e.g. the DRB1 locus would be known simply by the allele name, omitting the B1* (e.g. DRB1*0101 
becomes DR0101). DR1, DR2,... refer to the associated serologic specificities [50]. 
 The availability of the crystal structures of HLA molecules, initially reported for a HLA-class I molecule and 
later for class II molecules, has provided a breakthrough in the understanding of these molecules [51-53]. The 
basis of class I molecules is formed by ß2-microglobulin and the immunoglobulin-like α3 domain, while a 
distinct groove is formed by the α1 and α2 domain at the top of the HLA-molecule. This groove serves as a 
binding site for antigenic peptides for presentation to T cells. The 'floor' of the peptide binding cleft consists of 
ß-sheets, whereas the 'walls' are bound by extended regions of α-helical structure. The size of the antigenic 
peptides binding is generally 9 amino acids [54-57]. An analogous structure is found in HLA class II molecules, 
in that a peptide binding cleft sits on top of a base formed by the α2 and ß2 immunoglobulin-like domains 
(Figure 9). Moreover, the geometry of the cleft itself is highly similar, but not identical, to that found in the 
class I molecules. The major consequences of the differences in structure between HLA class I and II antigenic 
peptide binding grooves is that class II molecules can bind peptides that are longer and more variable in size; 
namely from 12 to 19 amino acids [51,57]. 
 A fundamental difference between class I and class II molecules, besides the different size of peptides bound 
in the cleft, is the source of these peptide antigens. Generally, class I molecules present peptide antigens derived 
from proteins that are actively synthesized within the endoplasmatic reticulum, whereas class II molecules 
present antigens taken up from outside the cell by endocytosis in vesicles called endosomes. These differences 
between class I and class II molecules are reflected by two distinct pathways of antigen processing and presen-
tation: the exogenous or MHC class II-restricted pathway and the endogenous or MHC class I-restricted 
pathway (Figure 10). The exogenous pathway operates e.g. during immunization with soluble protein antigens 
and stimulates a CD4+ T cell response. Human CD4+ T cells recognize short antigenic peptides present in the 
antigen-binding groove of HLA class II molecules at the surface of APC such as dendritic cells, macrophages 
and B cells. The antigenic peptides are derived by proteolytic cleavage of exogenous antigen that has been 
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phagocytosed or endocytosed by the APC and delivered into the lysosomal pathway where the derivative 
peptides associate with HLA class II molecules and are delivered to the cell surface for recognition by the 
appropriately rearranged T cell receptor (TCR) on a CD4+ T cell. The T cell subset specificity of this interaction 
derives from the fact that the multimolecular HLA-peptide-TCR complex is stabilized by accessory interactions 
such as those between the CD4 molecule on the T cell and the HLA class II molecule on the APC [reviewed in 
58,59]. A cytotoxic T lymphocyte response is stimulated by protein antigens processed in the alternative 
endogenous pathway. Human CD8+ T cells recognize short antigenic peptides (usually 9-11 residues) present in 
the antigen-binding groove of HLA class I molecules present at the surface of the cells. The antigenic peptides 
are derived by proteolytic cleavage in the proteasome of endogenously synthesized proteins in the cytoplasm. 
These may be self proteins, microbial- or tumor-derived molecules. The processed peptides are then bound by a 
family of transporter proteins (encoded within the HLA locus) which shuttle them into the lumen of the ER 
where they are scanned for the presence of HLA-allele-specific binding motifs by the antigen-binding domain 
of resident HLA class I proteins. Peptides containing the appropriate motif are tightly bound by the corres-
ponding HLA class I molecule which then associates with ß2-microglobulin and moves to the cell surface as an 
integral membrane protein where it can present the antigenic peptide to the T cell receptor on a CD8+ T cell. 
The T cell subset specificity of this interaction derives from the fact that the multimolecular HLA-peptide-TCR 
complex is stabilized by accessory interactions such as those between the CD8 molecule on the T cell and the 
HLA class I molecule involved in the complex [reviewed in 60]. Although there is a small amount of cross-talk 
between these two pathways, the CD4+ T cell response is principally class II restricted and regulatory in its 
function by secreting lymphokines which modulate the activity of antigen-specific B cells and CD8+ T cells as 
well as other CD4+ cells and macrophages. By the same token, the CD8+ T cell response is principally class I 
restricted and functions as the antigen-specific effector limb of the immune response as a CTL. 
 It is now accepted that costimulatory interactions are necessary for effective lymphocyte activation and also 
serve to enhance the immune response (Figure 11). Both the engagement of the TCR with MHC/Ag (first 
signal) and a second costimulatory signal are needed for the complete activation of the T cell. The CD28/B7 
receptor/ligand system is one of the dominant costimulatory pathways. CD28 interactions with the B7 family of 
costimulatory ligands are essential for initiating antigen-specific T cell responses, upregulating cytokine 
expression and promoting T cell expansion and differentiation. Interruption of this signaling pathway with 
CD28 antagonists not only results in the suppression of the immune response, but in some cases induces 
antigen-specific tolerance. However, the CD28/B7 system is increasingly complex due to the identification of 
multiple receptors and ligands with positive and negative signaling activities [61,62]. 
 
II.4.2. Human humoral immune response to HBV envelope proteins 
Serologic studies in HBV infection have clearly shown that structural and non-structural proteins are variably 
immunogenic at the B cell level. The HBsAg protein of the viral and subviral particles, although significantly 
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less immunogenic than HBcAg, displays the major B cell antigenic determinants that can induce a protective 
immune response. Serologically, HBsAg contains a common epitope, referred to as the group-specific 'a' 
determinant, and two sets of mutually-exclusive subtype determinants, 'd' or 'y' and 'w' or 'r'. The combination of 
the common (group) and subtype determinants results in the four major subtypes of HBsAg: adw, ayw, adr and 
ayr. In general, the anti-HBs immune response in humans mainly targets the 'a' determinant which is associated 
with all subtypes of HBV. Since recovery from infection by one subtype confers immunity to the others, and 
immunisation with one HBsAg subtype confers protection against HBV infection with all subtypes, it may be 
concluded that anti-a antibodies are protective [63]. It has been shown previously that the common 'a' deter-
minant is located between AA 124 and AA 147 [64]. Recent evidence however suggests that this epitope cluster 
could be extended up- and downstream to include the entire major hydrophilic region [9]. Studies suggest that 
the 'a' determinant contains several non-overlapping epitopes (Table 1), indicating that it is not a single 
determinant, but rather a conformation of several epitopes located on different regions of HBsAg. Since the 
exact disulfide linkage data are lacking, the tertiary structure of the 'a' determinant remains undefined. Varia-
tions at HBsAg-sites 122 and 160 alone define the d/y and w/r variations, respectively. More details about the 
group and subgroup determinants are described in [36]. The antibody response to HBV envelope antigens is 
strictly T cell-dependent, i.e. production of anti-envelope antibodies by immunization with the corresponding 
envelope proteins requires the presence of specific Th lymphocytes capable of recognizing and responding to T 
cell epitopes within the envelope region. The appearance of anti-envelope antibodies in a naturally infected 
subject indicates viral elimination. 
 Several groups have initiated studies to determine the occurrence and kinetics of antibody production to the 
preS1 region during acute and chronic HBV infection. It was found that antibodies to preS1 appear at the early 
stage of acute resolving HBV infection, but the antibodies are absent or of differing specificity in the sera of 
patients with acute HBV infection evolving towards chronicity and in the sera of chronic carriers [65,66]. In 
view of the early appearance of anti-preS1 in acute infection and its temporal relationship with clinical 
recovery, Alberti et al.[65] and Neurath et al.[67] analysed in detail the fine specificity of anti-preS1 antibodies. 
It was demonstrated that the preS1 sequence 12-32 is recognized by antibodies in sera of individuals recovering 
from HBV infection. It was noted that anti-(12-32) can be detected prior to anti-HBs or anti-HBc 
seroconversion but declines rapidly after production of anti-HBs and anti-HBc. The human anti-preS1 response 
can include multiple specificities since peptide sequences represented by 1-21, 12-32, 32-53, and 94-117 were 
variably recognized by sera from different HBV-infected patients. B-cell epitope 1-21 is unique to human sera 
and epitope 41-53 is unique to murine sera. The remainder of the B-cell sites are shared by mice and man. In a 
study of chronically infected patients [68], an interesting observation was that among asymptomatic carriers 
anti-preS1 was detected in those seropositive for anti-HBe but not in those positive for HBeAg. The authors 
suggested that anti-preS1 may have a role in clearing HBV from the circulation because preS1-containing 
polypeptides are preferentially expressed on virions. 
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 Several groups have examined in vivo antibody production to the preS2 region of HBsAg during HBV 
infection. Using a synthetic peptide representing residues 120-145 within the preS2 region, it was demonstrated 
that HBV-infected acute phase sera contain antibodies that recognize this sequence [67]. Examination of the 
fine specificity of antibodies reacting with the 120-145 sequence revealed that multiple specificities exist that 
primarily recognize the 133-143 epitope, which is also recognized by murine sera. The preS2-specific 
antibodies appear early during infection and decline in titer rather rapidly. Several studies have suggested a 
transient nature for antibodies to preS2 during HBV infection. No anti-preS2 was detected in acute patients who 
progressed to chronicity or in patients with chronic hepatitis with persistence of HBsAg and preS antigens 
regardless of HBeAg/anti-HBe status [69].  
 
II.4.3. Human cellular immune response to HBV envelope proteins.  
Sensitization of CD4+ lymphocytes to HBsAg proteins can rarely be demonstrated in HBV infected patients 
[70-74]. This may be explained by the very low frequency or absence of HBsAg-specific T cells but can also 
relate to the low immunogenicity of HBsAg (100-fold less compared with HBcAg in mice) and the lack of 
sensitivity of the cellular assays. When the T cell response to the envelope antigens is serially studied during 
acute infection it is weak. In contrast, the envelope-specific T cell response is usually quite strong in a good 
proportion of vaccine recipients who have been immunized with plasma-derived or recombinant HBsAg. 
Recognition of surface proteins by human T lymphocytes and their fine specificity has been studied in vaccine 
recipients as well as in patients suffering from acute and chronic infections (Table 1). Celis et al.[75] first 
described HBsAg-specific CD4+ T lymphocytes derived from peripheral blood of vaccine recipients. These T 
cell clones proliferated and produced IFNγ upon stimulation with HBsAg. They also supported anti-HBs 
production by autologous B lymphocytes in the presence of HBsAg. Another study of the same group mapped a 
dominant HBsAg-specific T cell recognition site to residues 193-202 (19-28) within the N-terminus of the S-
region. This immunodominant epitope is recognised in association with HLA-class II DPw4 molecules 
('restriction determinant') [76,77]. The majority of the HBsAg specific T cells exhibited both proliferative and 
cytotoxic responses, although they were phenotyped as being CD4+. Barnaba et al.[78] revealed that the 
overlapping region 193-207, was recognized in a DR2(15) context. Results from Penna et al.[79] indicate that 
HBV envelope-specific, HLA-class II restricted CD4+ CTL can potentially participate in the immune clearance 
of HBV-infected cells and the pathogenesis of hepatocellular injury in hepatitis B. Rao and coworkers 
demonstrated that peptide 124-147 of the S region encodes a dominant, conformational, group-specific epitope 
that is recognized by human anti-HBs Ab [80]. Further experiments revealed that this peptide also contains at 
least two T helper epitopes, one located between residues 124-137 and the other between residues 139-147 [81]. 
This was consistent with previous results from other laboratories [82]. Recently, Min et al.[83], Deulofeut et 
al.[84], and Honorati et al.[85] defined one and three new epitopes in HBsAg, respectively. 
 In another study, peripheral blood lymphocytes of 14 vaccine (plasma-derived) recipients were examined for 
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envelope-specific T cell activation [86]. All vaccine recipients displayed a significant proliferative T cell 
response to the S protein, eight subjects responded to the preS1 region product and only one person responded 
to the preS2 antigen. Limiting dilution studies in 2 vaccinated individuals showed that the precursor frequency 
of preS1-specific T cells was higher than that of S-specific T cells. Furthermore, preS1-specific T cell lines, 
besides their HBsAg-specific proliferation, show also HBsAg-specific HLA-class II restricted cytotoxic 
activity. It was concluded that the preS1-region is a strong immunogenic region in men. Unfortunately, the 
impact of the HBsAg subtype was not analysed in this study which could explain the low preS2 specific 
response. Subsequent studies, conducted by the same group and based on antigen recognition by T cell clones, 
mapped immunogenic epitopes within the preS1 protein; AA 21-30 and AA 29-48 [87]. Further experiments by 
Serra et al.[88] revealed that PBMC expressing DQ1(5) and DQ1(6) subtypes were very efficient in presenting 
peptide 21-30. A CD8+, MHC-class I restricted (HLA-A11) human T cell clone has also been derived from a 
vaccine recipient. The epitope recognized by the CD8+ clone was mapped to residues 21-28 within the preS1 
region [89]. Using Vaccinia/HBsAg recombinant vectors, these authors could demonstrate that class I- as well 
as class II-restricted T cell clones could recognise an endogenous expressed as well as an exogenous 
administered antigen. These results suggest that a subunit vaccine can induce class I-restricted T cells that are 
able to recognize virus infected cells. 
 Cupps et al.[90] studied the immunogenicity of the preS2 protein in vaccinated individuals and identified a 
number of serotype-specific T cel epitopes in this region. The most important epitope for T cell proliferation 
was localised in the preS2 (AA 146-165) region (adw subtype). Cross-reactivity with ayw serotype-specific 
peptides not included in the preS2-S vaccine, was limited. This observation can be useful for further vaccine 
development. Steward et al.[91] identified the AA 126-140 within the preS2 region as a T epitope. Barnaba et 
al.[92,93] have examined T cell sensitization to HBsAg proteins in patients suffering from chronic HBV 
infections. MHC class I- and class II- restricted T cell clones were generated from liver infiltrating lymphocytes 
that were stimulated in vitro with preS2 containing HBsAg particles. These clones recognized determinants 
within the preS2 residues 120-134, suggesting that this sequence can bind to MHC class I and MHC class II 
molecules. Specific cytotoxic responses against HLA-matched EBV-immortalized lines sensitised with HBsAg 
particles or peptide 120-134 were displayed by both types of clones. This indicates that preS2 specific T cells 
are present within the liver during chronic infection and that these cells may mediate hepatocellular lysis. These 
investigators have also suggested a mechanism whereby pre-S2-specific cytotoxic T lymphocytes may lyse 
HBsAg-specific B cells that present envelope peptides in the context of the MHC-class I pathway [93]. Such a 
mechanism would result in the suppression of anti-HBs production, observed during chronic infection.  
 Anti-viral CTL are believed to play a major role in eradication of infection by virtue of their capacity to 
identify and kill virus-infected cells through recognition of viral peptides presented by HLA class I molecules. 
Due to the restricted host-range of HBV and its lack of infectivity in vitro, the CTL response to this virus has 
been very difficult to study. Thanks to the analysis of MHC bound peptides, a procedure pioneered by 
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Rammensee and coworkers [94], it has become possible to define the epitopes within the envelope protein 
recognised by human CD8+ lymphocytes during acute hepatitis B. By using a strategy involving in vitro 
stimulation of PBMC with HBV-derived peptides, selected according to the HLA-A2 binding motif as des-
cribed by Rammensee's group, Nayersina et al.[95] showed that most patients with acute viral hepatitis produce 
a CTL response to several HLA-A2 restricted epitopes. They demonstrated that the CTL response in acutely i-
nfected patients is polyclonal and multispecific within the individual patient and is absent in uninfected healthy 
volunteers and chronically infected patients. For the first time these data confirm directly the involvement of 
virus-specific CTL in host defence during acute hepatitis B virus infection and support the hypothesis that viral 
persistence may be related to a low level CTL response in chronically infected patients. Only recently, Reher-
mann et al.[96] were able to demonstrate that chronically infected patients who experience a spontaneous or 
interferon-induced remission develop a CTL response to HBV that is similar in strength and specificity to 
patients who have recovered from acute hepatitis. The HLA-A2 restricted envelope-specific CTLs recognizing 
amino acid residues 194-202 and 346-354 were identified. These results suggest that specific 
immunotherapeutic enhancement of the CTL response to HBV should be possible in chronically infected 
patients, and that it could lead to viral clearance in these individuals. 
 It is widely believed that the HBV is completely cleared by antiviral antibodies and specific CTLs during 
acute viral hepatitis. However, it was demonstrated recently that traces of HBV are often detectable in the blood 
for many years after clinical recovery from acute hepatitis, despite the presence of serum antibodies and HBV-
specific-CTLs, which can be present at acute-stage levels. These results suggest that complete clearance of HBV 
frequently fails to occur after recovery from acute hepatitis and that traces of virus are kept under the control of 
a vigilant immune system for decades following clinical recovery [97]. When the immune system is severely 
depressed (endstage renal disease, HIV infection, immunosuppressive therapy,..) reactivation of the HBV 
remnant may occur.  
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II.5. Current data on hepatitis B vaccination 
II.5.1. General 
The single most important tool for the prevention and control of hepatitis B infections is the hepatitis B vaccine. 
The first experiments on active immunisation against hepatitis B were reported by Krugman et al.[23]. 
Nowadays, active immunisation against HBV infection is common practice. Since antibodies to the HBsAg 
have been shown to be effective in preventing infection after exposure to this agent, the development of an 
efficient vaccine has slowed down the steady increase of chronic HBV hepatitis, liver cirrhosis and HCC. 
Systematic vaccination of neonates born from HBV chronic carrier mothers prevents the development of 
chronic carriership in these children and so disrupts the vicious circle. To date, the rationale for universal 
immunisation of neonates against HBV in countries with high or intermediate endemicity of HBV is widely 
accepted [126]. Indeed, over 40 countries are in the process of introducing universal HBV immunisation into 
the activities of their EPI program (Expanded Programme on Immunisation), or have already done so (Figure 
12)[127,128]. The EPI is a multinational effort to immunise all of the world's children against the immunisable 
diseases of childhood. If consistently applied, this policy may lead to elimination of hepatitis B as a serious 
disease of humankind by the year 2050 (Figure 13). Cost is the major limiting factor affecting implementation 
of universal immunisation to neonates in Africa and most Asian countries. Data obtained through cost-benefit 
analysis in the past decade repeatedly suggest a long-term benefit of such an immunisation policy [130]. 
However, many countries are unable to allocate the short-term funds necessary to introduce an effective 
prevention program against HBV, even though the long-term cost-benefit analysis justifies such an effort. 
 The 'first generation' hepatitis B vaccines were obtained by purification and heat-inactivation of HBsAg 
particles that were derived from the plasma of chronic HBV carriers [63,131,132]. The first plasma-derived 
hepatitis B vaccines (PDV) were licenced in France and the U.S.[63] in 1980 and became available since 1982. 
These vaccines were the first such products to be manufactured from human plasma and possessed the 
additional attribute of being the first anti-cancer vaccines to become available for human use. Their safety and 
immunogenicity was demonstrated in many studies with healthy individuals and with persons belonging to 
higher risk groups (homosexual men [63,133], health care workers [134], haemodialysis patients [135,136],..). 
The high cost-price and the limited supply of plasma of chronically infected persons are disadvantages of these 
vaccines. Furthermore, the fear, although groundless, concerning the biological safety of these products, has 
hampered the general acceptance of this vaccine. The recombinant DNA technology induced the development 
of 'second generation' hepatitis B vaccines. The HBsAg, present in these vaccines, is produced by recombinant 
yeast or mammalian cells wherein the HBsAg gene (S gene) is cloned [137-139]. These recombinant, yeast-
derived vaccines (YDV) became commercially available in 1986 and are now in use worldwide [140]. Both 
plasma and yeast derived vaccines have had an excellent safety record. Large scale production of non-glyco-
sylated HBsAg in yeasts is already cost-effective, and costs are declining rapidly. The available HBV vaccines, 
whether PDV or YDV, are highly immunogenic, leading to 90 to 96% seroconversion rates in pediatric and 
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young adult populations [141]. 
 Although currently available HB vaccines are very immunogenic, not all vaccinees are able to mount a 
protective antibody titer after a correct administration of 3 or more vaccine doses. Approximately 1 to 3% of 
neoborns and up to 6% of immunocompetent adults produce no or inadequate (<10 IU/l) anti-HBs levels after 
vaccination [7]. Since little is known about the T cell priming effect of an unsuccessful vaccination, nonrespon-
ders should be considered to run the same risk for HBV infection as unvaccinated subjects. Little is known 
about the course of an acute HBV infection in nonresponders, but the few reports available suggest that the 
severity and evolution towards chronicity in vaccine nonresponders is not different from that observed in 
unvaccinated subjects [142-144]. Furthermore, there are a number of target populations which do not readily 
seroconvert when immunised with the conventional HBV vaccines. These groups include older adults and 
therapy- or disease-related immunodeficient patients (e.g. chronic dialysis patients, HIV-infected individu-
als,...)[145]. Chronic carriers of HBV (healthy, asymptomatic carriers as well as chronic active hepatitis 
patients) are also characterized by a deficient humoral response to HBsAg [146]. Since the appearance of anti-
HBs predicts recovery in acutely infected persons, clinicians hope to overcome chronicity in these individuals 
by therapeutic vaccination with HBsAg [147,148]. Unfortunately, the results of such therapeutic vaccination 
trials have been deceiving.  
 The presence of nonresponders to the available hepatitis B vaccines, and the finding that the strength of the 
initial immune response to the vaccine is an important contributing factor in the duration of the protection [149], 
argued in favour of the development of a more immunogenic vaccine that induces a protective antibody titer in 
all vaccinees. The research in HB vaccinology is concentrated mainly on the development of this 'third gener-
ation' vaccines. 
 
II.5.2. Immune response to the HB vaccine 
More than a decade of experience in hepatitis B vaccination has shown that the immune response to the 
hepatitis B vaccine in healthy subjects is extremely variable. Following administration of 3 doses of vaccine 
under optimal conditions, most recipients produce a high-titered and long-lasting anti-HBs response. However, 
5 to 10% of healthy vaccinees respond slowly and poorly (anti-HBs titer ≤ 100 IU/l) and maintain protective 
antibody levels (≥ 10 IU/l) for only very limited periods. Approximately 1 to 3% of neonates and up to 10% of 
healthy adults do not produce adequate levels (<10 IU/l) of antibodies after 3 doses of the currently available 
vaccines, and can be considered nonresponders [150]. This nonresponsiveness is a selective phenomenon and is 
not the expression of a general immune deficiency. This update will concentrate on the HB vaccine 
nonresponsiveness as observed in healthy individuals. 
 The immune response to the hepatitis B vaccine is determined by numerous immunisation and host factors. 
Immunisation factors include the dose of vaccine administered, the vaccination schedule, the site and route of 
immunisation, and the storage conditions of the vaccine. Numerous clinical trials and more than 10 years of 
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experience in the field have shown that optimal results are achieved when 3 or 4 doses of 20 µg of HBsAg 
vaccine are administered intramuscularly in the deltoid region at 0, 1 and 6 months or at 0, 1, 2 and 12 months, 
respectively [151]. Host-related factors which influence the response to hepatitis vaccination include age, 
gender, bodyweight, smoking habits and disease state. The immune response to hepatitis B vaccine, expressed 
in both seroconversion rate and the geometric mean anti-HBs titer, declines with increasing age [141,152,153]. 
Obesity and smoking also have an adverse effect on the anti-HBs response [154-157]. In general, women 
produce a better immune response than men, and this may be related to hormonal and postural or bodyweight 
differences between both sexes [158]. Moreover, conditions which impair the function of the immune system 
may hamper the response to the vaccine. This has been observed in homosexual men infected with the human 
immunodeficiency virus (HIV) [159-161] and in intravenous drug users [162]. Approximately 40% of haemo-
dialysis patients [163-165] and 70 to 80% of organ transplant recipients receiving immunosuppressive therapy 
[166,167] cannot mount adequate anti-HBs responses. Apart from the usual host-related factors which account 
for this variability in immune response, a genetic factor is recognised as a possible cause of nonresponse. 
 
II.5.3. Genetic control of the immune response to the HB vaccine: MHC class II association 
II.5.3.1. Genetic control of the murine immune response to HBsAg  
Through the work of Milich et al. much is known about the regulation of the immune response to HBsAg in a 
murine model [8,98,100,109,168-170]. The most important findings are the following:  
a) the humoral immune response of different inbred mouse strains to HBsAg is highly variable.  
b) The antibody production after immunisation of mice with HBsAg is controlled by the MHC-system. A 
marked influence of the H-2 linked immune response genes on the kinetics and magnitude of the anti-HBs 
production was shown. High responder (H-2d,q), intermediate to low responder (H-2a,b,k), and nonresponder (H-
2s,f) haplotypes can be identified [8,168,169].  
c) The production of preS2-specific antibodies, generated after immunisation with preS2-S or preS1-preS2-S 
particles, is also controlled by the H-2 system.  
d) The genetic regulation of the immune response to preS2 and preS1 antigens is independent of the immune 
response to the S antigen. After immunisation with preS2-S particles of H-2s mice (nonresponder to S, but 
responder to preS2), S-specific antibodies were produced besides preS2-specific antibodies [170]. After immu-
nisation with preS1-preS2-S particles of H-2f mice (nonresponder to S and preS2, but responder to preS1) S and 
preS2-specific antibodies were produced besides preS1-specific antibodies [109]. Analysis of the S- and preS-
specific T responses revealed that the mechanism that permits circumvention of this nonresponsiveness, can be 
situated at the T cell level. The ability to induce a S- and preS-specific response in non-responder mouse strains 
after immunization with preS1-preS2-S particles suggests that these mice have preS1-specific T cells who can 
help not only preS1-specific, but also S- and preS2-specific B cells [98].  
e) The humoral immune response to the group-specific 'a' and the subtype-specific 'd' and 'y' determinants of 
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HBsAg is controlled by H-2 linked immune response genes [100].   
f) Responsiveness to HBsAg is inherited as a dominant trait, whereas nonresponsiveness is inherited as a 
recessive trait.  
g) no evidence for immune suppression was found in nonresponder mice. 
 
II.5.3.2. Genetic control of the human immune response to HBsAg  
The suggestion that genetic mechanisms may control the human immune response to HBsAg was made by 
different authors who found a statistically significant association between certain HLA-haplotypes and 
nonresponsiveness to the HB vaccine (Table 2). In the literature we will find two opposit opinions concerning 
this nonresponsiveness. Both theses will be discussed in detail and can be summarized as follows: 1) a normal 
response to HBsAg is due to the presence of one or more dominant immune response gen(es) positioned in the 
HLA-region; poor or nonresponsiveness on the other hand is caused by the absence of these gene(s) and the 
presence on both chromosomes of HLA-haplotypes inducing a nonresponse. In this vision, the lack of a normal 
response was a recessive MHC-linked trait [171-176]; 2) the absence of a humoral immune response to HBsAg 
is caused by the presence of an immune suppression gene located in the HLA-region. Nonresponse is then 
inherited as a dominant trait and is mediated by CD8+, HBsAg-specific suppressor T lymphocytes [177,178]. 
 The suggestion that MHC-linked genes may control the human immune response to HBsAg was first made 
in 1981 by Walker et al.[171]. A significant excess of HLA-DR7 and a total absence of HLA-DR1 was 
observed in a group of 23 subjects showing a very weak or absent anti-HBs response to 3 doses of vaccine. This 
observation was later confirmed and extended by other investigators. In hypo- and nonresponders to a first 
series of 3 hepatitis B vaccines, HLA-DR7 [172,173] and HLA-DR3 [173,174] were found more frequently 
than in the general population. A greater than expected number of homozygotes for the extended MHC 
haplotype (HLA-B8/SCO1/DR3) was observed in low/nonresponders, which suggested that the lack of a 
normal response was a recessive MHC-linked trait. This hypothesis was subsequently confirmed in a study 
wherein 5 homozygotes and 9 heterozygotes for the extended haplotype (HLA-B8/SCO1/DR3) were prospec-
tively vaccinated [176]. Four of the 5 homozygotes produced low levels (<1000 RIA units) of anti-HBs, 
whereas all 9 heterozygotes produced normal levels of antibody. It was concluded that a normal humoral 
response to HBsAg was governed by a dominant immune response gene located in the MHC, and that low or 
nonresponsiveness was caused by the absence of this gene and the presence on both chromosomes of a reces-
sive inherited MHC-linked non-response gene(s) for HBsAg. Recently, it was shown that the genes encoding 
the HLA-DQ2 are subtyped into DQB1*0201 (in linkage disequilibrium with DR3) and DQB1*0202 (in 
linkage disequilibrium with DR7). The lack of antibody response to HBsAg vaccination was shown to be 
significantly associated with the HLA haplotype DRB1*0701-DQB1*0202. A second HLA haplotype, 
DRB1*0701-DQB1*0303, on the other hand, was not associated with the lack of antibody response to HBsAg 
vaccination, indicating a crucial role for the DQB1*0202 allele [179].  
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 A different hypothesis on the mechanism of nonresponsiveness to HBsAg has been put forward by 
Sasazuki's group [175,177,178]. These investigators immunised 85 healthy Japanese volunteers via the subcu-
taneous route with 3 doses of a plasma-derived vaccine. Four weeks after the third dose, 19 subjects (22,4%) 
showed no anti-HBs response. Among the nonresponders there was a significant increase of the HLA-
Bw54/DR4/DRw53 haplotype. This research group further showed that responsiveness to HBsAg was a 
recessive trait, whereas nonresponsiveness was transmitted dominantly and was mediated by CD8+, HBsAg-
specific suppressor T lymphocytes. The increased incidence of the HLA-Bw54/DR4/ DRw53 haplotype in 
nonresponders, as well as the dominant inheritance pattern of this nonresponsiveness and the role of suppressor 
T cells in its expression are observations made only by Sasazuki's group [177]. These unique results may be 
related to the oriental origin of the subjects studied and/or the subcutaneous vaccination route used. 
 Although HLA-identical siblings generally produce virtually identical levels of anti-HBs, the dramatic 
difference in antibody responses observed in one pair [180] suggests that unidentified, non-MHC-linked factors 
may influence the anti-HBs response. 
 
II.5.4. Immunological mechanism responsible for HBsAg nonresponsiveness  
 Literature describes a lot of phenomena which can explain the lack of a normal response to HBsAg after 
vaccination. Although some immunological mechanisms were analysed, an univocal explanation for the origin 
of this nonresponsiveness could not yet be found. Most publications on this topic can roughly be divided in two 
opposite opinions. A number of researchers (especially Japanese groups) propose the 'suppression hypothesis' 
wherein inheritance of nonresponsiveness would be dominant. However, most other groups argue against this 
hypothesis and suggest that the failure to respond to HBsAg is an MHC-determined recessive trait whereas the 
ability to mount an adequate antibody response is dominant. Both hypotheses are based on the observed MHC 
class II association in HBsAg vaccine nonresponsiveness. The MHC is thought to operate at least in two ways 
to mediate the immune response, via direct binding of processed peptides to class II MHC molecules as part of 
antigen presentation to CD4+ helper T cells [185-187] and in the selection of T cells in the thymus or peripheral 
lymphoid organs with specific T cell antigen receptor (TCR) molecules [188,189]. In mice and humans there 
was an excellent correspondence between the in vivo anti-HBs level and in vitro T cell proliferation to HBsAg 
with nonresponders showing no T cell proliferation [190,191]. This and other observations suggest that the 
defect in nonresponder animals resides at the level of the T cell-APC interaction. This has also been shown for 
many other T-dependent immune responses [192,193].  
 
II.5.4.1. The 'presentation defect' and 'determinant selection' hypotheses 
In many studies in mouse [47] and in man [194] the lack of response to foreign antigens has been shown to be 
mediated primarily by the lack of binding of peptides to APC. There can be a failure of antigen uptake, 
processing, or interaction of processed antigen with MHC class II molecules. These mechanisms would lead to 
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defective antigen presentation with resultant failure to activate potentially activalable CD4+ T helper cells. For 
this mechanism, unresponsiveness would have to be recessive, requiring the defect to be specified by both of a 
nonresponder's MHC haplotypes. 
 T cells appear to recognize a limited repertoire of sites on a protein antigen. The estimate of diversity came 
from studies in mice of the recognition specificities for model protein antigens: myoglobin, cytochrome C or 
lysozyme [195,196]. In each instance it was found that T cells respond to a small number of regions of the 
protein molecule in a haplotype-specific manner. Therefore it was postulated that the function of MHC 
molecules is to specifically bind some peptides, but not all that are created during processing. This was called 
the 'determinant selection' hypothesis for MHC molecules. 
 Defective MHC binding is the most common explanation for lack of immune response to antigens such as 
hen egg lysozyme, ovalbumine, cytochrome C, and protein staphylococcal nuclease [197,198]. Since HBsAg 
gives rise to a limited number of immunogenic peptides [169], individuals with certain MHC alleles could fail 
to respond to the entire antigen, as their class II antigens can fail to bind to a major immunogenic peptide. Thus 
in its simplest form this hypothesis suggests that the non-responder status is the result of the inability of antigens 
to bind to MHC molecules leading to a failure of T cell stimulation. 
It was demonstrated that low or nonresponders at the antibody level also failed to mount in vitro T cell 
lymphoproliferative responses to HBsAg. We [199] and others [200] performed T cell-APC mixing experiments 
using responder T cells and nonresponder APC (NR-APC), and concluded that defective MHC binding or 
antigen processing is not the basis for nonresponse. However, in these experiments we only analysed the 
potential of NR-APC to recall a T cell response and not the capability to induce a primary response. The 
presentation or priming capacity of dendritic cells from NR remains to be analysed. 
 General mechanisms for nonresponse, including deficient enzyme systems or enzyme inhibitors, may also be 
operative. However, the normal response to other vaccine (tetanus toxoid) or viral (Varicella Zoster) antigens in 
HBsAg nonresponders makes this unlikely. 
 
II.5.4.2. The 'hole in the T cell repertoire' or 'shared epitope' hypothesis. 
HBsAg contains a number of immunogenic peptides and is expected to be a good immunogen. However the 
observed lack of response to this antigen can be due to the absence or dysfunction of HBsAg-specific T cells. 
This defect could be due to a physical (thymic selection) or functional deletion (anergic state) of these T cells. 
  
 Strong binding of a peptide to MHC molecules is not enough for immunodominance. For a peptide derived 
from the bacteriophage lambda cI repressor, it could be shown that it was a strong binder but was not 
recognized by T cells. This peptide displayed homology to a self peptide of the Ia molecules which explained 
the absence of a T cell response [48]. Schaeffer et al.[201] studied 14 overlapping peptides that span the entire 
staphylococcal nuclease protein. Each of these peptides was incubated with Ia molecules and its binding was 
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determined. 30% of the peptides could bind Ia and, of these, 70% could elicit a T cell response. These findings 
provided evidence for 'holes in the T cell repertoire' and further showed that Ia molecules have a specific, 
though broadly permissive, capacity to bind peptides from a protein. 
 During thymic development many potential T cell receptor combinations are deleted and as a consequence 
there are 'holes in the T cell antigen recognition repertoire'. These holes are induced by specific MHC molecules 
during thymic education of T cells [201] or in the periphery. This mechanism would lead to unresponsiveness 
resident in T cells and not APC. One postulated mechanism in vivo by which the T cell defect in response to 
any antigen including HBsAg could have arisen is through molecular mimicry of a foreign epitope by protein 
encoded by self polymorphic non-MHC loci [186]. Evidence for such a mechanism was obtained in mouse 
experiments with a synthetic terpolymer [202]. Furthermore, numerous experiments have now been shown that 
MHC molecules can present self proteins [203]. For example, De Koster et al.[204] showed that one allele of a 
DP molecule could present an epitope of a DR molecule. This implies that self-proteins may be competing for 
foreigns for presentation. 
 A nice example of the involvement of molecular mimicry was described for a bovine leukemia virus (BLV)-
associated pathology. The relationship between polymorphism of the bovine lymphocyte Ag (BoLA)-DRB3 
gene and resistance and susceptibility to persistent lymphocytosis (PL) caused by BLV was investigated. A four 
amino acid homology between susceptibility-associated DRB3 alleles and BLV pol was found indicating that 
susceptibility to the subclinical progression of BLV infection could involve molecular mimicry [205]. 
 
II.5.4.3. The 'suppression' and 'Th1-Th2' hypothesis.  
In this hypothesis the failure to respond to foreign antigens is mediated by the MHC-determined presence or 
excess of antigen-specific suppressor (CD8+ or Th2 CD4+) or CD8+ CTL reacting against APC carrying a 
particular peptide [206] or against Th1 T helper cells of a particular specificity. Only one MHC haplotype 
would suffice for the effect, and inheritance of the nonresponse would be dominant. 
A number of early studies compared the lymphocytic subsets and the PBL-proliferation to aspecific stimuli 
(mitogens) of responders and nonresponders to the HBsAg vaccine. Nowicki et al.[207] demonstrated that 
nonresponder (n=17) PBL posses significant higher amounts of CD2+ (T11+), CD57+(HNK-1+) and CD8+ (T8+) 
lymphocytes than responders (n=20). Furthermore, the nonresponder PBL show a reduced IgM and IgG 
production in vitro after PWM-stimulation. This led to the hypothesis that nonresponders have a larger popula-
tion of T suppressor cells which influenced their normal immune response to the HB vaccine. This theory was 
confirmed by Japanse investigators [208], who postulated that, based on coculture experiments, nonresponse in 
the early faze is caused by a B cell defect and in a later fase is due to the presence of HBsAg-specific T sup-
pressor cells. These authors found a dominantly expressed, MHC-linked CD8+ T cell mediated suppression 
among the 20% of Japanese subjects who failed to respond to HBsAg immunisation. These findings were in 
contrast with observations by Egea et al.[190] who were unable to demonstrate any difference between R and 
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NR lymphocytic subsets, nor in proliferation upon PWM, PHA or TT. This study also analyzed the HBsAg-
specific proliferation of T cells in the presence or absence of autologous CD8+ T cells. No immune suppression 
could be demonstrated. Furthermore, removal of CD8+ (suppressor) T cells did not result in T cell proliferation 
in nonresponder peripheral blood mononuclear cells [209]. These more recent results strongly suggest that 
neither cytotoxicity nor suppression via CD8+ or Th2 cells plays an important role in the nonresponse to 
HBsAg. The Boston group postulated that nonresponders have a very specific (HBsAg-related) defect at the 
level of their antigen presentation and/or T cell stimulation. 
  
II.5.4.4. The 'silent infection' hypothesis.  
Recently a novel cause for nonresponsiveness to hepatitis B vaccines has been proposed. A Japanese [210] and 
a Chinese [211] study revealed that sera of some individuals who did not develop anti-HBs after repeated 
vaccination, were positive for HBV-DNA. Therefore it was proposed that immune tolerance or immune sup-
pression, due to a latent low-level infection with the hepatitis B virus, may account for part of the nonres-
ponsiveness to HB vaccination observed in Japan. We and others [199,209] could not detect HBV-DNA in sera 
from Caucasian nonresponders. The HBV-DNA detection method used was one of the most sensitive methods 
available today (Enzymun test/DNA detection that is applied on PCR-amplified specimens). We dare to 
conclude that the hypothesis formulated by Takahashi and Luo is only applicable for the Oriental population 
and may explain but a part of the observed nonresponsiveness. 
 
II.5.5. Strategies to overcome nonresponsiveness to the HB vaccine 
A first approach to overcome nonresponsiveness, is the design of a more immunogenic HBV envelope vaccine. 
This was done by adding preS1 and preS2 sequences to the conventional HBsAg vaccine. The underlying 
rationale for this approach can be found in mouse experiments. Studies in the murine model have shown that the 
immune response to the preS1 and preS2 regions of the HBsAg are regulated independently from the S region 
response, such that immunisation of S region nonresponder/preS2 region responder mice (H-2s) with a preS2 
containing particle (HBsAg/p33) circumvented nonresponse to the S region [212]. Similarly, immunisation of S 
and preS2 region nonresponder mice (H-2f) with preS1 containing particles (HBsAg/p39) circumvented this 
nonresponsiveness and resulted in the production of antibodies against the S, preS2 and preS1 regions [109]. 
The independence of MHC-linked gene regulation of the immune response to the preS1, preS2 and S regions of 
HBsAg would assume fewer genetic nonresponders to a vaccine containing all 3 regions. Furthermore, in vitro 
neutralisation experiments and in vivo immunisation with preS synthetic peptides have shown that preS2 and 
preS1 specific antibodies in the absence of S region antibody can protect chimpanzees against infection [213]. 
The results of a study suggesting that preS1 antigen may be a strong T cell immunogen in humans warranted 
further studies to determine the necessity and/or advantages of the inclusion of preS sequences in third 
generation hepatitis B vaccines. Several experimental preS-containing vaccines have been produced and have 
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been under evaluation for a number of years. Clinical vaccine trials yielded mixed results. The early human 
trials using preS2-containing vaccines proved safe and immunogenic, but indicated no distinct advantage over 
the existing S region-only vaccines [214,215]. Our own experience using a recombinant hepatitis B vaccine 
containing selected regions of the preS1 and preS2 sequences was rather deceiving [216,217]. However, in the 
same time frame, groups using preS2-containing [218,219] or preS1+preS2-containing [220] vaccines reported 
that the inclusion of the preS sequences conferred clear advantages. More recent trials using either preS2- or 
(preS1+preS2)-containing recombinant HBsAg vaccines seem to confirm that the preS sequences do confer 
distinct advantages including an early seroconversion to anti-preS2, which circumvents the problem of delayed 
appearance of anti-HBs antibodies in some vaccinees especially neonates, and efficacy in nonresponders to 
previous S region-only vaccines [221-224]. One reason for the more recent successes may be the inclusion of 
the preS1 region or components of preS1 sequences which were not included in the two earlier trials. 
Furthermore, different investigators have independently explored an alternative expression system for HBV 
surface proteins using the mammalian-derived Chinese hamster ovary (CHO) cell line [222-226]. To date, 
CHO-derived vaccines containing glycosylated and non-glycosylated S and preS2 proteins have been tested in 
mice and humans. Data suggest a markedly enhanced anti-HBs response and a lower rate of non- and hypo-
responders. However, until now, the efficacy of preS-containing HBsAg vaccines remains a controversial 
subject. In different studies appropriate control groups were omitted. These 'third-generation' experimental 
vaccines will be judged mainly based on their potential property of inducing higher seroconversion rates, but 
not necessarily the higher anti-HBs titers. Finally, development of new improved vaccines should by no means 
affect the continually increasing distribution of the conventional vaccines for prevention of HBV worldwide.  
 A number of characteristics of the immune response to HBcAg suggest that this antigen may be useful for 
HBV and non-HBV vaccine development. For example: HBcAg has been shown to represent an efficient 
immunogen at the T-and B cell levels both in mice and man; the particulate HBcAg can elicit T cell indepen-
dent as well as T cell dependent antibody responses; HBcAg is efficiently processed and presented by APCs; 
native HBcAg particles ensure strong T cell help not only to intrinsic B epitopes, but also to the non-HBcAg 
epitopes associated with it. Furthermore it was shown that HBcAg-specific Th cells can stimulate antibody 
production to HBcAg as well as to HBsAg, when both antigens are present within the HBV particle [227]. 
These characteristics suggested that HBcAg may be an ideal carrier moiety for B cell epitopes requiring 
additional Th function. Therefore, a number of HBV and non-HBV B cell epitopes have been chemically linked 
or fused by recombinant methods to HBcAg particles as a method to increase immunogenicity with significant 
success [228,229]. Studies of positional effects have demonstrated that an internal insertion into a dominant 
HBcAg-specific B cell site represents a superior location for enhanced antibody production [230]. Positive 
results were obtained using HBcAg as a carrier moiety for FMDV (foot-and-mouth disease virus) peptide, 
poliovirus type 1 C3 epitope, human rhinovirus type 2 epitope, FeLV (feline leukaemia virus) epitope, a HIV-
gag sequence (human immunodeficiency virus),...[231]. The HBcAg was recently used as a carrier moiety for 
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malarial circumsporozoite antibody epitopes inserted into the surface loop structures. Efficient anti-malarial 
antibody and Th cell responses were elicited and the mice were protected against a challenge infection [232]. 
Instead of particulate HBcAg, it was shown that synthetic T cell sites derived from the HBcAg sequence can 
also function as carriers for B cell epitopes of the envelope of HBV and HIV ('peptide vaccine')[233]. These 
results indicate that HBcAg or synthetic T cell sites of HBcAg, or both, may represent an efficient T cell carrier 
moiety for multivalent vaccine development. 
 There has also been interest in the potential of DNA immunisation for prophylactic vaccination against 
HBV. In murine studies, intramuscular injection of plasmid DNA encoding the S region or the S region and the 
preS(2) region of the HBV envelope has been reported to induce anti-HBs and anti-preS(2) antibody production 
[234], potent CD8+ CTL activity in a responder strain [235] and in a strain nonresponsive to other immunisation 
methods [236], and predominantly Th1-like CD4+ responses [237]. Immunisation with plasmid DNA encoding 
HBsAg also elicited significant levels of anti-HBs in chimpanzees [238]. The humoral and the cellular 
responses occurred soon after DNA injection in mice (i.e. antibody, 1-2 weeks; CTL, 3-6 days) and persisted for 
4-6 months after a single DNA injection. It has also been recently reported that the use of plasmids coexpressing 
IL2 and envelope proteins of HBV resulted in enhanced humoral and cellular immune responses [239]. Whether 
DNA-based immunisation proves to be more effective, less expensive or safer than recombinant proteins 
remains to be determined. However, DNA immunization may prove to be useful therapeutically in CH-B 
carriers.  
 In mice with genetically determined nonresponsiveness to HBsAg, several strategies which permit 
circumvention of this nonresponsiveness have been identified. Mice bearing the H-2s haplotype are 
nonresponsive to intraperitoneal immunisation with 4 to 20 µg of HBsAg in Complete Freund's Adjuvant 
(CFA). Increasing the dose of antigen to 40 µg or changing the route of vaccine administration to footpad 
injection induced an anti-HBs response [240]. Immunisation of nonresponder mice with HBsAg conjugated to 
sheep erythrocytes (SRBC) resulted in an IgG anti-d specific response after a single dose but failed to induce an 
anti-a response after primary or secondary immunisation. Native HBsAg nonresponder SJL (H-2s) mice produ-
ced low but detectable levels of anti-HBs when immunised with synthetic peptide analogues of HBsAg 
determinants [240]. These studies indicated that the B cell repertoire of nonresponder mice was intact and that 
nonresponsiveness could be circumvented by enhancing nonspecific T helper function. 
 The effect of additional vaccine doses on nonresponsiveness has been examined by several investigators. 
Wismans et al.[241] and Jilg et al.[242] found that intramuscular administration of 3 supplementary doses to 
healthy hyporesponders and nonresponders after a standard vaccination course induced a protective (≥10 IU/L) 
anti-HBs response in 75% of the subjects. In our study [217], using an identical experimental set-up, we found a 
seroprotection rate of 90% after 3 supplementary vaccine doses. Two Japanese groups [243,244] showed that 
intradermal injection of 5 µg HBsAg at 2-weekly intervals induced a positive (≥10 IU/L) anti-HBs response and 
a delayed-type hypersensitivity reaction in all subjects. These observations suggest that in humans (as well as in 
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mice) B cells with anti-HBs specificity are present in genetic nonresponders. These B cells can be incited to 
produce and secrete anti-HBs as soon as they receive adequate T cell help. 
 The use of immunomodulators or strong adjuvants is one of the many strategies to enhance the immune 
response. Adjuvants are thought to improve immune responses 1) by causing depot formation at the injection 
site (delay of immunogen release), 2) by acting as delivery vehicles for antigens, and 3) by acting as immunosti-
mulators (improved presentation to T cells) [245,246]. Lipopolysaccharide (LPS) and more specifically its lipid 
A component has for long been known for its strong adjuvant effect. However toxicity precluded its use in a 
vaccine formulation. Ribi et al.[247] have shown however that a monophosphorylated form of lipid A (MPL) 
retains its adjuvant function and almost completely loses its endotoxin effects. More recently a 3-deacylated 
form of MPL has been shown to have a further decrease in its toxicity as tested in small animals, while retaining 
its immunopotentiating effect [248]. The commercially available 3-D-MPL is derived (3-deacylated) from the 
LPS of the gram negative Salmonella minnesota. Recent immunogenicity studies in mice have shown that MPL 
specifically induces antigen-specific Th1 type T cells and thereby significantly improves IFNγ production. 
Although animal experiments have shown that MPL mainly stimulates the cellular arm of the immunity, it also 
induces a stronger and faster anti-HBs antibody response. Vaccination trials with this new adjuvant are 
presently underway.  
 The effect of nonspecific immunostimulation of the murine immune response to HBsAg or related peptides 
has been examined in different studies. Coupling of the immunostimulatory sequences of interleukin 1ß (IL-1ß) 
in tandem with amino acids 12-32 from the preS1 sequence elicited an increased primary and secondary anti-
S/12-32 response [249]. The humoral and cellular immune response of mice and guinea-pigs to HBsAg when 
alum-precipitated or administered with Syntex Adjuvant Formulation (SAF) were compared. SAF induced an 
increased and more consistent anti-HBs response in young mice and low responder strains. SAF allowed the 
reduction of the HBsAg dose to one-tenth of that required to elicit similar antibody responses by alum-
adjuvanted HBsAg [250]. Algammulin, a new vaccine adjuvant comprising a stable suspension of 1 to 2 µm 
ovoids of the immune stimulant gamma inulin in which alum is embedded as a protein carrier, was shown to 
have a greater adjuvanticity than alum for HBsAg in mice [251]. 
 Several strategies to overcome nonresponsiveness to HBsAg have been explored in haemodialysis patients. 
Increasing the antigen dose or administration of immune adjuvants such as interleukin-2 [252,253], interferon γ 
[254], interferon α [255] or thymopentin [256] improved the anti-HBs response. A recent report shows that 
treatment of haemodialysis patients with recombinant human erythropoietin increases antibody titers after 
hepatitis B vaccination [257]. This effect may be due to the avoidance of transfusion and a direct upregulation 
by erythropoietin of T and B cell function. Systematic studies exploring the effect of immunomodulating agents 
on the anti-HBs response in genetic nonresponders to HBsAg have not yet been performed.  
 
II.5.6. HBV vaccination in newborns and infants 
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The immunogenicity and safety of hepatitis B vaccines have been analysed in neonates and infants [258]. 
Inadequate responses to hepatitis B vaccine occur in approximately 5-15% of neonates [259]. In 1997 the 
Belgian governement has decided to include the hepatitis B vaccine into the standard infant immunisation 
programs, a decision that is however not yet implemented [260]. The persistence of protective anti-HBs levels 
in groups of children who had been immunised against hepatitis B 5 and 10 years earlier, during their first year 
of life, has been studied. In Italy, the absence of core antibody (anti-HBc) in responders to the vaccination 
shows the protective efficacy of both the recombinant yeast and plasma-derived vaccines. On the other hand, 
the presence of anti-HBc in some anti-HBs negative nonresponder subjects shows the susceptibility of these 
subjects to HBV infection [261]. The results of an Iranian study [262] indicate that a significant proportion of 
the nonresponder neonates to HBsAg can be induced to develop a protective and long-lasting antibody response 
by administration of a single additional vaccine dose. The disappearance, in some children, of protective levels 
of anti-HBs in the years following vaccination does not mean that all protection against HBV infection is lost. 
In fact, the trial showed that these children reacted immediately to booster stimulation, demonstrating a solid 
immunologic memory. Therefore, there may be no need to give booster injections when the vaccination of 
infants is carried out correctly [263]. 
 Maternal-infant transmission and transmission in early childhood are important means by which the virus 
persists in the population. Each year, thousands of infants are born to women who are positive for HBsAg. 
These infants are at high risk for perinatal HBV infection and for chronic liver disease as adults. Without 
immunoprophylaxis, 70 to 90% of infants infected during the neonatal period or in the early infancy, will 
become chronic carriers (Table 3)[264]. In Africa, the majority of infections are acquired between the age of 6 
months and 6 years. To identify newborns who require immunoprophylaxis to prevent perinatal HBV infection, 
all vaccine advisory groups have recommended routine HBsAg screening of all pregnant women during an 
early prenatal visit in each pregnancy [265]. In order to prevent vertical transmission of HBV, infants born to 
HBsAg-positive women, receive hepatitis B immune globulin (HBIG) and a first dose of hepatitis B vaccine at 
birth (passive-active hepatitis B immunisation), with follow-up doses of vaccine at ages 1 and 6 months. 
Vaccination alone is efficacious in preventing the development of HB in these children, but its efficacy 
increased with the concomitant use of HBIG [266-268]. It was shown that the protective efficacy of passive-
active hepatitis B vaccination is mainly influenced by maternal HBV-DNA levels, and independent of time of 
starting active vaccination at birth or at 3 months of age. Additional measures are needed to protect neonates of 
highly viremic women [269,270]. Around 20% of newborns to mothers chronically infected by the HBV did not 
produce antibodies after correct vaccination. An in utero induced immune tolerance to low doses of HBsAg 
appears the most plausible hypothesis to explain this unresponsiveness to HBV vaccine [271].  
 
II.5.7. Therapeutic vaccination  
Vaccines can also be used to treat disease, not just to prevent it [147]. Since patients with a chronic hepatitis B 
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virus infection are characterized serologically by the absence of anti-HBs in the routinely used anti-HBs assays 
[272], it was appealing to consider HB vaccination for the treatment of these patients. 
 The rationale for the development of therapeutic vaccines in chronic hepatitis B is based on the hypothesis 
that vaccination should revert either a state of unresponsiveness due to tolerance or a state of disturbed 
immunity. Either of these states would be responsible for the chronic hepatitis. First, since the humoral response 
to HBsAg is enhanced by a vaccine coupled to a strong adjuvant, this may break the host's tolerance towards the 
virus and induce the production of anti-HBs antibodies. Second, CTL activity, through its recognition of viral 
antigen in the context of HLA-proteins at the liver membrane surface, is probably the main mechanism involved 
in the clearance of the virus via the destruction of infected hepatocytes. 
 In vitro and in vivo animal experiments have shown that some adjuvants are strong stimulants of cellular 
immunity, especially of the Th1 type [245]. These adjuvants will thus also enhance the production of IFNγ 
which has been shown to play an important role in the clearance of virus, by downregulating viral replication 
and facilitating destruction of infected hepatocytes. Inclusion of an immunostimulant should favor the induction 
of a Th1 T cell response against the HBV antigen. In addition, non HBV derived T cell epitopes should favor 
reversal of a state of anti-HBsAg T cell tolerance. Therefore, new vaccines could favor the establishment of an 
effective virus clearing immune response that would translate in seroconversion to anti-HBs, decrease of 
circulating HBV-DNA and, most probably, a transient rise in liver enzymes, the so-called flare-up, that heralds 
viral clearance.  
 The potential use of vaccines for the treatment of chronic hepatitis B patients has first been examined in 
HBsAg-transgenic mice. These mice were vaccinated and produced anti-HBs [273,274]. Later on the 
woodchuck- and Pecking Duck-model were tested [275,276]. 
 Until now, at least three groups conducted human trials wherein chronically HBV-infected patients were 
vaccinated. The vaccines used were plasma-derived HBsAg [277,278] or recombinant HBsAg, containing 
preS2 sequences [279]. In the study by Dienstag et al.[277] there was no evidence that HBV vaccine was 
effective in eliminating HBV. By contrast, Pol et al.[148,279] reported that vaccination of chronic carriers with 
HBsAg containing the preS2 region lowered HBV replication and reduced HBV-DNA to undetectable levels. 
Wen et al.[278] immunised patients with chronic hepatitis B infection, with hepatitis B vaccine complexed to 
human hepatitis B immunoglobulin. They found that 9/14 patients became negative for serum HBV-DNA after 
three immunisations with this complex. All groups reported that vaccination appeared to be safe, with no side-
effects, and no anti-HBs antibodies were detected after immunisation. 
 A synthetic peptide vaccine containing a CTL epitope of HBcAg (AA 18-27) and a Th epitope of tetanus 
toxoid (AA 830-843) is currently being investigated as a means of treating chronic hepatitis B infection [280]. 
Until now, results indicate that HBV-specific immune responses can be effectively elicited by synthetic 
immunogens at the level of T and B cell recognition, and that development of a synthetic HBV vaccine is 
feasable. Although a synthetic peptide-based HBV vaccine is probably not necessary in view of the effective 
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recombinant vaccines, 'targeted' therapeutic uses for synthetic Th cell, CTL, and antibody recognition sites may 
be envisioned. In this context, the enhanced immunogenicity of HBcAg as compared to HBsAg, the ability of 
HBcAg to act as a T-cell-dependent antigen, and the relevance of HBcAg to protective immunity, suggest that 
HBcAg may represent an ideal carrier moiety for HBV antigens [231]. 
 Whether therapeutic vaccination, by stimulating the cellular and humoral immunity and by presenting 
different epitopes to the immune system, could break the host's immune tolerance to the virus in chronic 
hepatitis B and induce a seroconversion, remains to be further explored. Although the development of vaccines 
with greater immunogenicity is very important in the future, care must be taken since the administration of 
exogenous HBsAg can induce CTL which increases liver cell destruction. Gene therapy [281,282] and 
immunotherapy (e.g. passive transfer of immune cells, bone marrow transplantation from hepatitis B 
immunized donors [283], cytokine therapy,...) are other possible therapeutic tools that can be useful in the future 
[284,285]. 
  
II.5.8. HBV vaccination and antigenic variability 
II.5.8.1. Antigenic variability: general 
Nucleotide substitutions in viral genomes can have several effects, including evasion of vaccine-induced or 
natural immunity, drug resistance, changes in pathogenicity, alterations in tissue or species tropism, and viral 
persistence. Viral genomes, particularly those of RNA viruses, are subject to inherent variability due to the 
incorrect incorporation of nucleotides during viral replication and an inefficient mutation repair system. The 
mutation rate is about 1 mutation in 1x103 to 1x104 nucleotides for each replication cycle of RNA viruses. DNA 
viruses have a much lower mutation rate of about 1 mutation in 1x105 nucleotides per replication cycle 
[286,287]. The high mutation rate of RNA viruses is partly due to the properties of RNA polymerases/reverse 
transcriptases. In contrast to DNA polymerases, the RNA enzymes are not capable of correcting errors in 
nucleotide incorporation during polynucleotide synthesis ('lack of proof-reading function'). Thus, in the course 
of every viral infection - albeit with variable frequency in RNA and DNA viruses - mutations will occur, 
resulting in the emergence of variants. Obviously, to be competent, a variant must be able to infect efficiently, 
to replicate and to resist the defence mechanisms of the host.  
 The existence of HBV variants has been suspected for many years. This assumption was based on the 
detection of viral DNA and RNA in patients with chronic hepatitis in the absence of serological evidence of an 
HBV infection. In recent years, the systematic identification of HBV variants was made possible by the 
development of PCR, which enables the amplification of viral DNA or RNA in vitro. Although mutations in all 
viral genes and some regulatory genetic elements have been detected, two types of mutations seem to be very 
important and are referred to as precore mutants, and mutations in the common 'a' determinant of HBsAg [288-
291].   
 The variability of HBV viruses is estimated to be intermediate between DNA- and RNA viruses [288]. HBV, 
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a DNA virus, replicates via an intermediate RNA stage with the use of reverse transcriptase. This enzyme is 
found in association with the virion and has no proofreading activity. It might therefore be expected that HBV 
viruses have a high mutation rate. But there are constraints on the ability of HBV to accept mutations without 
becoming non-viable. The genome is only about 3200 bases long, the smallest of any DNA virus that infects 
man, and all the genetic material codes for proteins with the regulatory elements being found within these 
coding regions. A mutation will thus most probably lead to a non-viable virus. This explains the rather small 
mutation-ratio that is seen in HBV viruses. Nevertheless, mutations in each of the four open reading frames 
were found in HBV viruses. 
 As documented in hepatitis B and C, genomes of hepatitis viruses frequently mutate during the course of 
disease. When such mutations occur in the region coding for antigenic epitopes recognized by the host's 
immune system, the viral change may lead to modulation of disease activity. For example, a single base 
substitution in the precore region of the HBV genome might induce activation of hepatitis from an immune 
tolerant state. Since HBV infections may persist for many years or even decades, mutations will accumulate 
over time and may become clinically relevant. The selection and accumulation of certain mutants depend not 
only on the time factor and on the replication activity, but also on the rate of elimination of wild-type viruses 
and the resistance towards antiviral mechanisms or drugs, amongst many other factors. 
 Mutations in the precore, core, surface, and polymerase genes have been studied in association with specific 
clinical conditions. The major protective epitope of HBV (the 'a' determinant) is believed to form two loops on 
the outside of the virus [292]. It is found in all known subtypes of HBV, and binds most of the anti-HBs found 
in hyperimmune serum. Mutations within this 'a' determinant have been described and most cases had a 
mutation from glycine to arginine at AA position 145 of HBsAg (named G145R)[289-293]. The mutant was 
identified for the first time in 1990 during the course of a passive (hepatitis B immune globulin)-active (HB 
vaccine) HBV immunisation program in southern Italy. Several neonates of HBV carrier mothers were 
observed to have become infected with HBV despite a primary response (adequate anti-HBs titer) to the HBsAg 
vaccine. Molecular analyses showed that one of these children was infected with a HBV mutant [289], 
exhibiting a defect in the S region of the HBV genome. This single amino acid change at position 145 probably 
induces a configurational change in the second external loop with loss of the group-specific antigenic 'a' deter-
minant, the main target antigen of the vaccine response. By consequence the vaccine-induced antibodies cannot 
recognize the modified surface antigen anymore (Figure 14) [294]. This viral mutant was thus able to escape the 
immune surveillance, to replicate as a competent virus and thereby cause an infection despite the presence of 
anti-HBs antibodies ('vaccine escape mutant'). Since then, similar mutants have been detected in Japan, Spain, 
the United States, Great Britain, Singapore, Gambia. Presumably this mutation occurs worldwide [291]. Fur-
thermore, this mutation has also been reported in patients after liver transplantation for HBV-related chronic 
liver disease who had received monoclonal anti-HBs antibodies in an attempt to prevent reinfection of the graft 
[295]. It is supposed that these mutants have appeared under pressure generated by anti-HBs antibodies, both 
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vaccine-induced and passively administered. Because HBV infection is diagnosed by the serological detection 
of antigens or antibodies, it is conceivable that, in addition to 'vaccine escape mutants', 'diagnosis escape 
mutants' will also exist. A change in the HBV antigenic structure can influence the sensitivity of these serolo-
gical tests. Mutant HBsAg can be detected by some, but not all commercial kits [292]. The non-detection of 
HBsAg can lead to the transfusion of infectious blood or the transplantation of infected organs. Changes 
elsewhere in the 'a' determinant, or in other domains of the S protein (surface gene mutants) have been reported, 
although the significance of these findings is obscure [296]. 
 Mutations have further been detected in the preS1 or preS2 regions of the HBV genome, but their clinical 
significance remains unknown [296]. Deletions rather than single-point mutations appear most often. Deletion 
mutants of up to one-half of the entire preS1 region were detected in 2 out of 10 individuals with chronic HBV 
infections following the initiation of interferon treatment. However, a mixture of wild-type and deleted forms 
was always observed [297]. In the study of Yamamoto et al. [298], deletions of up to 60 base pairs were found 
in at least 3 of 6 asymptomatic carriers, principally at the N-terminus of preS2. Furthermore, truncated integra-
ted preS2-S gene sequences have a transcriptional transactivator function and appear to be associated with the 
development of HCC [299]. Whether these genomic changes result in a replication-competent virus is uncertain. 
The role of the immune response to the preS proteins has received less attention than the role of anti-HBS in 
viral neutralisation and elimination. However, preS-antibodies precede the development of anti-HBs during 
clearance of the virus. Furthermore, immunisation with just the amino terminal region of preS2 protects chim-
panzees from HBV challenge [107]. So it is possible that mutations within the preS genes, as they have been 
described in patients with chronic HBV infection, can influence the normal viral neutralisation or elimination. 
 
II.5.8.2. Implications for HBV vaccination 
Since these mutant viruses can infect individuals with anti-HBs, it is very unlikely that current vaccines would 
protect against infection with this mutant. Until now, there are no data on the prevalence of these S gene 
mutants in the vaccinated population or the population at large. Their stability over time, their transmissibility 
within a population, the factors which promote their development, and thus the importance of these 'escape' mu-
tants has yet to be established. Still, there is no evidence at this time that they pose a threat to immunization 
programs [38]. However, immune pressure on the population is occurring now as more countries take up 
universal vaccination. 
 It is very clear that G145R is the most stable and common variant seen after vaccination. The simplest 
solution is to vaccinate everybody with both G145- and R145- containing vaccines. The currently available 
vaccines are composed of S gene products derived from the wild type sequences. If S gene mutants are 
prevalent, future vaccines may need to be based upon both the S and preS gene product. In fact the preS region 
is a potent stimulant of T cell activity and may thus be a mechanism of enhancing immunoresponsiveness in 
patients with HBV variants.  
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  Recently it was found that certain mutations in the polymerase gene of the HBV confer resistance to 
lamivudine [300]. Since the polymerase gene entirely overlaps the surface gene of HBV these mutations will 
also induce changes in the HBsAg gene. Thus the treatment of chronically infected HBV patients with 
lamivudine can seriously disturb the HBsAg-immunology post-treatment, and perhaps preclude a possible 
therapeutic vaccination. 
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III. Outline and aims of this thesis: introduction to the experimental work 
HBV causes acute and chronic liver diseases of variable severity by mechanisms that are thought to be largely 
immune mediated. Prevention of HBV-infection through vaccination has been routinely practiced and antibo-
dies to the HBsAg have been shown to be effective in preventing infection after exposure to this agent. Follo-
wing vaccination or natural acute HBV infection with recovery, significant titers of anti-HBs develop. However, 
approximately 5 to 10% of healthy vaccine recipients fail to produce protective levels of antibodies to the 
hepatitis B vaccine after standard immunisation. This phenomenon has been observed in all vaccine evaluation 
studies, irrespective of the HBsAg vaccine used. Although the cause of this humoral unresponsiveness remains 
unclear, it was repeatedly observed that NR not only display no, or low, humoral immune responses in vivo, but 
also fail to mount a lymphoproliferative response upon stimulation with HBsAg in vitro. Furthermore, a firm 
correlation between vaccine nonresponsiveness and certain HLA haplotypes was observed. The group of vacci-
nees that are genetically predestinated to become HBsAg vaccine nonresponders are discussed in this thesis.  
 The distinction between acute and chronic HBV infection is based on the clearance or persistence of 
envelope particles (HBsAg) and HBV-virions. Chronic HBV infections (5 to 10% of infected individuals) are 
almost certainly caused by a failure to mount an appropriate immune response to HBV. Until now, most studies 
reveal a defective production of neutralizing anti-HBs antibodies in these patients. Since the appearance of anti-
HBs predicts complete recovery in acutely infected individuals, protects against reinfections in convalescent pa-
tients and protects against primary infections in vaccinees, a defect in this humoral response may be a key factor 
in establishing the carrier state. The causes of the defective anti-HBs production in patients with chronic HBV 
infections are completely unknown. Previous studies, based on vaccination data, have demonstrated that there is 
a critical requirement for T cells in the humoral response to HBsAg. In HBV carriers however, with one 
exception, the majority of studies has failed to demonstrate peripheral T lymphocyte sensitization to HBsAg.  
 Inadequate humoral and cellular immune responsiveness to HBsAg has thus been observed in vaccine 
nonresponders as well as in chronically infected individuals. Whether the mechanisms responsible for this 
HBsAg unresponsiveness are identical in both groups remains to be determined. The research presented in this 
thesis aimed at unravelling this HBsAg unresponsiveness and analysed the human cellular reaction which 
ensues after HBsAg-vaccination in healthy individuals. The methods used to analyse the immune response in 
vaccine NR can be helpful in the future to elucidate the etiology of HBsAg unresponsiveness in chronically 
infected individuals and can - in the long run - contribute to a better understanding of the pathogenesis of this 
disease.  
 The results of our research efforts are presented in chapter IV as a compilation of 8 manuscripts. Three have 
been published, one is in press, three have recently been submitted for publication and one is still in preparation. 
These manuscripts are organized in 4 sections according to the questions they address. In Section IV.1. we 
present the results of our study of the genetic factors that influence the human immune response to hepatitis B 
vaccines. This single paper provides answers to immediate study objectives 1 and 2. Section IV.2. encompasses 
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two manuscripts that summarize our exploration of the mechanisms of nonresponse to hepatitis B vaccines. 
These reports provide answers to immediate study objectives 3 and 4. Section IV.3. encompasses two 
manuscripts. One deals with the phenotypic and functional qualities of a series of HBsAg-specific T cell lines. 
The second paper reports on our analysis of the T cell recognition of HBsAg by PBMC from good responder 
vaccinees. This section tries to answer immediate study objectives 5, 6 and 7. Section IV.4. represents our 
contribution to the design and evaluation of 'improved' HB vaccines. Two companion papers summarize the 
results of two clinical evaluations of a candidate third generation HB vaccine containing selected preS1 and 
preS2 in addition to the entire S sequence. A third manuscript describes our immunological analysis of a 
delipidated HBsAg and demonstrates how delipidation improves T cell immunogenicity but reduces B cell 
immunogenicity to HBsAg. This section provides answers to immediate study goals 8 and 9. 
 
The aims of this thesis were the following: 
A. Immediate objectives  
 1. Determination of HLA-class II molecules linked with good and/or poor response to the HBsAg vaccine. 
 2. Analysis of interactions between HLA-factors involved in poor responsiveness. 
 3. Analysis of HBsAg-presentation capacity of APC derived from HB vaccine nonresponders. 
 4. Analysis of B7-costimulation in good and poor responders to the HBsAg. 
 5. Identification of immuno-dominant T cell epitopes of the HBsAg at the population level. 
 6. Development of HBsAg-specific T cell lines in HBsAg good and poor responders. 
 7. Identification of epitope- and HLA-restriction of these HBsAg-specific T cell lines. 
 8. Analysis of the immunogenicity of a preS-containing HBsAg vaccine. 
 9. Analysis of the immunogenicity of delipidated HBsAg. 
 
B. Long-term objectives 
 * Elucidation of the etiology of HBsAg-unresponsiveness in HB vaccine nonresponders. 
 * Elucidation of the etiology of HBsAg-unresponsiveness in HB chronic carriers. 
 * Development of a new, more immunogenic vaccine that induces a protective anti-HBs response in ALL 
vaccinated individuals, if possible with fewer vaccine doses. 
 * Development of a therapeutic vaccine to cure chronically infected patients.  
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IV. Publications 
IV.1. Genetic factors influence the human immune response to hepatitis 
     B vaccines 
    Response to hepatitis B vaccine: multiple HLA genes are involved  
 
 
    Isabelle N. Desombere, Annick Willems, and Geert G. Leroux-Roels 
 
 
    Running Title: HLA and response to hepatitis B vaccine 
 
 
    Key words: Hepatitis B surface antigen, Hepatitis B vaccines, HLA antigens,   
                     immune response, nonresponse 
 
 
    Published in: Tissue Antigens (preprint) 
 
 
    Remark: The publication is presented in its 'preprint' form. We apologize for the  
   minor typographic errors. 
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V. Conclusions and general discussion 
V.1. Conclusions 
The experimental data obtained in this study have led us to the following conclusions: 
 
1. The human immune response to HBsAg is influenced by genes located in the MHC class II region. 
Although the mechanisms causing inadequate immune responses to HBsAg-vaccines in 10% of healthy young 
adults remain largely unknown, variations in the immune response are often associated with polymorphism of 
the MHC. In mice, the anti-HBs production is controlled by the H-2 system. An increased incidence of poor 
responsiveness in subjects with HLA-DR3 and/or -DR7 haplotypes has been documented, suggesting that HLA-
DR-linked genes may regulate the human response to HBsAg. In chapter IV.1 of this thesis we analyzed the 
association between MHC and the human humoral immune response to the hepatitis B vaccine. By correlating 
HLA haplotypes of vaccinees to their HBsAg response patterns, we were able to identify HLA markers associa-
ted with good response (HLA-DRB1*010*, -DR5, -DPB1*040*, -DQB1*0301, and -DQB1*0501) and HLA-
markers associated with non/poor response to HBsAg (HLA-DRB1*07, -DPB1*1101, and -DQB1*020*). This 
was the first indication that HLA-DP molecules, besides HLA-DR and -DQ, influence the human immune 
response to HBsAg. We further found that HLA-DPB1*02 was negatively associated with responsiveness when 
it occurred in association with haplotype DRB1*0701/DRB4*0101-DQB1*020*, and DRB4*0101 was 
negatively associated with responsiveness when it occurred in association with haplotype 
DRB1*0301/DRB3*0101-DQB1*020*. Clearly, interactions between HLA molecules that are not in linkage 
disequilibrium contribute to poor responsiveness. 
 Homozygosity for HLA-DR3, -DR7 and -DQ2 tended to be positively associated with nonresponsiveness. 
Seven HLA-DR7, 7 HLA-DR3 and 19 HLA-DQ2 homozygous individuals were observed in the non/poor 
responder population, whereas only 1 homozygous DR7, 1 homozygous DR3 and 2 homozygous DQ2 
individuals were observed among good responders (Figure 15). Recently, heterozygosity at these HLA class II 
loci (HLA-DR and -DQ) was shown to be associated with protection from persistent HBV infection [1].   
 These data represent strong evidence for a role of MHC class II molecules in HBsAg-vaccine 
unresponsiveness. 
 
2. The nonresponsiveness to HBsAg vaccine in HLA-DR7+ and/or -DR3+ subjects does not reside in a defect of 
HBsAg presentation of their PBMC.  
In chapter IV.2. of this thesis we present the studies we have performed in an attempt to unravel the mecha-
nism(s) responsible for the immunological unresponsiveness to HBsAg. Theoretically, nonresponsiveness to 
HBsAg vaccines may be caused by a defect (alone or in combination) at each of the numerous stages involved 
in the human immune response. However, the correlation between in vivo humoral and in vitro cellular respon-
ses and the known critical requirement for T cells in the anti-HBs response suggests that the inadequate 
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antibody production in vivo may be caused by a lack of adequate T cell help. For these reasons we focused on 
the initial processes of the immunological cascade, namely the capacity of APC to present HBsAg. Since 
several reports described an increased incidence of nonresponsiveness in subjects with the HLA-DR3 and/or -
DR7 haplotype, we concentrated our research on individuals expressing these HLA molecules. We were able to 
demonstrate that our inability to detect a T cell response in vaccine NR was not caused by a defective HBsAg-
presentation of their APC. HBsAg-presentation capacity was analyzed in HLA-DR2+ ,-DR7+ and -DR3+ 
nonresponders to the hepatitis B vaccine. This functional analysis of HBsAg-processing and -presentation was 
performed with a series of HBsAg-specific T cell lines or clones with known antigen fine-specificity (peptide 
fragment) and HLA-restriction. Antigen was presented to these T cells through haploidentical responder and 
nonresponder APC. Since T cell clones/lines do not require costimulation for their proliferation, a defect at the 
B7-CD28 level could not be excluded in these individuals. For this reason, we further analyzed the quality of 
the costimulatory signals B7.1. and B7.2. in these individuals.  
 
3. B7.2.-costimulation is probably not deficient in NR  
In this thesis we demonstrate that CD86, which is primarily involved in the induction of an optimal T response 
with recall antigens and which is normally constitutively expressed on human peripheral blood monocytes, was 
not downregulated after culturing PBMC from NR with HBsAg. This was analyzed in an HLA-DR3 and -DR7 
homozygous context. We conclude that B7-costimulation is probably not deficient in non/poor responders to 
the hepatitis B vaccine.  
 
4. Several HBsAg-derived T helper epitopes are involved in responsiveness to hepatitis B vaccines. 
In the past, our group has clearly demonstrated that there is a critical requirement for T cells in the humoral 
response to HBsAg. Since a close correlation between the in vivo humoral (anti-HBs production) and the in 
vitro cellular (T cell proliferation) responses to HBsAg has been demonstrated in HB vaccine recipients and in 
patients with an acute HBV infection, it was tempting to speculate that the magnitude of anti-HBs responses is 
largely determined by the quality and magnitude of the HBsAg-specific T cell responses. For these reasons we 
embarked on a more detailed analysis of the human T cell response to HBsAg in vaccine recipients. We thus 
identified a number of immunodominant T epitopes in the HBsAg. Six of them were recognized preferentially 
(immuno-dominant epitopes) by a group of 32 high-responder vaccinees (population-level). Other T cell 
epitopes of HBsAg were identified by analyzing the fine specificity of a series of HBsAg-specific T cell lines. 
The identification of immunodominant T cell epitopes can be helpful in understanding the etiology of HBsAg 
unresponsiveness and in the development of new vaccines. 
 In chapter IV.3. we describe our efforts to map T cell epitopes on the HBsAg. In Figure 16 an updated T cell 
epitope map of the HBsAg is given. It clearly shows that numerous T cell epitopes are scattered over the 
HBsAg sequence. This leads us to the concept that in the APC a large number of different peptides are 
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generated by processing of HBsAg. A substantial number of these peptides are capable to interact with the HLA 
class II molecules expressed by that cell. Despite the numerous T cell epitopes that were identified, HBsAg 
remains a notoriously poor T cell immunogen (e.g. compared to HBcAg), inducing only a weak T cell 
proliferative response with short-lived memory.    
 
5. The first hydrophobic region of the HBsAg is highly immunogenic at the T-cell level in man. 
The majority of HBsAg-reactive T cell clones/lines (10 out of 12) recognize sequences located in the first 
hydrophobic region. Figure 16 also shows that especially the first hydrophobic region HBsAg contains a cluster 
of several overlapping T cell epitopes. Whether this immunogenicity resides in the AA composition of this 
domain or in its topography in the HBsAg particle remains to be determined. 
 
6. DRB1*0701 and DPB1*0402 interact with and present the same AA sequence in HBsAg 
HLA-DP0402 and -DR0701 can both present the HBsAg-derived peptide 193-207. The described HLA binding 
motifs for these HLA molecules can be found in this AA sequence. These results indicate that sequence 193-
207 contains a cluster of at least two overlapping T cell epitopes. Surprisingly, this peptide can be presented by 
an HLA molecule associated with a good humoral vaccine response (HLA-DP0402), and with an HLA 
molecule known to be associated with non/poor responsiveness. The impact of this observation, however, 
remains unknown.  
 
7. Poor responders to HB vaccine recognize fewer T cell epitopes than good responders 
A limited analysis of the T cell epitopes of HBsAg recognized by good and poor responders to HBsAg vaccine 
revealed that good responders generally recognize multiple sites within the HBsAg sequence. Numerous T cells 
with different specificities are thus triggered upon stimulation with HBsAg and this explains the vigourous 
nature of the response in good responders. It is extremely difficult to raise T cell lines or clones from poor 
responders and these turn out to be directed towards one or a very limited number of epitopes. The 
pauciclonality of the T cell response in poor responders probably explains the absence and weakness of their T 
cells, and overall response to the vaccine.  
 
8. Addition of selected preS-sequences to existing HB vaccines did not enhance the in vivo humoral anti-HBs 
response in young healthy adults, nor in established poor responders.  
A number of target populations do not readily seroconvert when immunized with the conventional HBV 
vaccine. These groups include immunosuppressed patients, chronic hemodialysis patients, and elderly people. 
Furthermore, 5 to 10% of healthy young adults are unresponsive to HBsAg. These different groups make it 
worthwhile to continue the search for more immunogenic HB vaccines. Furthermore the reduction of the 
number of vaccine doses can decrease the costs of vaccination and increase the compliance. In an attempt to 
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circumvent HBsAg-vaccine unresponsiveness, we analysed whether modifications of the hepatitis B vaccine 
can improve the induced immune response. Based on clinical observations in natural HBV infection and 
experimental evidence obtained in mice and chimpansees, SmithKline Beecham Biologicals has designed a 
recombinant HB vaccine containing selected preS1- and preS2 sequences in addition to the full length HBsAg 
sequence. This molecule was called L* and was coexpressed with HBsAg in S. cerevisiae, called S-L*. In one 
study we compared the safety and immunogenicity of SL* with that of Engerix-B in two groups of young, 
healthy adults. In a second study we examined whether S-L* induced a faster or higher anti-HBs response as 
compared to Engerix-B within a group of 32 healthy adults with an established poor response to existing HB 
vaccines. These studies led to the following conclusions: 
 * Addition of the selected preS sequences to S did not enhance the in vivo humoral anti-HBs response in 
young healthy adults, but improved the in vitro stimulating capacity of the antigen (L*) in S-L* primed subjects. 
 * Addition of preS sequences to S did not enhance the in vivo humoral anti-HBs response in established 
poor responders. 
 * The addition of three additional vaccine doses, irrespective of their preS content, induces seroprotective 
anti-HBs levels in 91% of the originally poor-responding vaccinees. 
 * In vitro proliferative response to HBV envelope antigens were only observed in poor-responding subjects 
displaying anti-HBs titers > 1000 IU/l after the third additional vaccine dose. 
 
9. Partial delipidation improves the T cell immunogenicity of hepatitis B surface antigen.   
 The remarkable composition and variable immunogenicity of the HBsAg incited us to analyse whether the 
delipidation of HBsAg particles alters the immunogenicity of the antigen. Earlier publications reported that 
delipidation of HBsAg with detergents or phospholipase C, could alter the immunogenicity of the HBsAg 
particle. The underlying rationale was that the high lipid content (+/- 40%) of the HBsAg particles might 
represent an obstacle to the successful processing and presentation of the antigen on top of the constraints 
already imposed upon the system by HLA restriction. Partial delipidation of the particles could favour the 
immunogenicity of the particle by facilitating the lipid digestion and enhancing the accessibility for processing 
of the protein moiety. To examine this issue we treated HBsAg with the non-denaturing detergent ß-D-octyl 
glucoside (chapter IV.4.3.) and analyzed the immunogenicity of these altered particles in vitro as well as in 
vivo. These studies led to the following conclusions: 
 *  The delipidated particle induced better T cell responses than its untreated counterpart and this as well in 
good responders, nonresponder vaccinees and chronic hepatitis patients. 
 * Delipidated HBsAg alone has a significantly reduced B cell immunogenicity (antibody recognition) as 
compared to native HBsAg. 
 * When native and delipidated particles were mixed, the amount of native HBsAg needed to mount a normal 
response, can be considerably reduced. 
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V.2. General discussion 
 Whether a vaccine will induce an adequate immune response in a vaccinee will depend on qualities of the 
host and on the intrinsic properties of the vaccine. In this thesis we studied in detail the T cell response against a 
well defined structural protein of the HBV, the hepatitis B surface antigen (HBsAg), which is currently used as 
hepatitis B vaccine. Immune response to HBsAg was studied in both good and poor responders to this vaccine.  
 Several immunological mechanisms have been put forward to explain nonresponsiveness to the T-dependent 
HBsAg, but the exact nature of this problem remains unidentified. Recent data enfeeble the 'suppression' 
hypothesis for nonresponsiveness, in which HBsAg-recognition induces negative signals ('suppression') which 
selectively suppress a normal humoral anti-HBs response. Also the hypothesis suggesting a 'B cell repertoire 
defect', in which B cells recognizing HBsAg and/or synthesize the appropriate anti-HBs molecules 
(immunoglobulines) are absent, became very unlikely considering the fact that most NR to HBsAg (human and 
mouse) were able to produce anti-HBs when stimulated more vigorously (sometimes up to 12 doses are 
needed). Today, several observations suggest that the defect in nonresponders resides at the level of the T cell-
APC interaction, as has been shown for many other T-dependent immune responses. In mice and humans there 
was an excellent correspondence between the in vivo anti-HBs level and in vitro T cell proliferation to HBsAg, 
with nonresponders showing no T cell proliferation; in other words, HBsAg-specific B and T cell responses are 
closely correlated. Since the generation of an anti-HBs response requires cooperation between HBsAg-specific 
T and B lymphocytes, the absence or reduction of T cells may lead to a defective or absent anti-HBs response. 
Furthermore, there are strong arguments for a role of HLA-class II molecules in the human immune response to 
HBsAg; genes associated with good and poor response as well as gene complementation has been observed. 
However, the precise linkage between HLA and HBsAg responsiveness is not understood.  
 The quality of particular HLA haplotypes (e.g. HLA-DR3, -DR7, -DQ2,..) can mediate the immune 
response via direct binding of processed peptides to HLA class II molecules as part of antigen presentation to 
CD4+ helper T cells. Thus particular HLA molecules can be responsible for a deficient HBsAg-presentation, i.e. 
peptides generated during processing are unable to fit in the peptide binding groove of MHC class II molecules. 
By consequence, no peptide/MHC complexes will be presented at the surface of the APC. We speculate that 
this occurs for HLA-DQ2 molecules. We assume that no HBsAg-derived peptides can stably interact with these 
molecules. This is based on the finding that the published DQ2-binding motifs, although the peptide-binding 
specificities of human HLA-DQ MHC class II proteins are still controversial, do not occur in the entire HBsAg-
sequence [2]. Furthermore, we nor others were able to demonstrate the existence of DQ2-restricted HBsAg-
specific T cells.   
 Surprisingly, HLA-DR3 and -DR7 molecules can adequately present HBsAg to T lymphocytes and no B7-
costimulation defect could be observed in these NR. A HBsAg-specific deficiency in the T cell population 
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seems the most likely explanation for these NR. It remains to be determined whether these cells are absent, fail 
to recognize the antigen or are anergized. A hole in the T cell repertoire by elimination or anergization of 
HBsAg-specific T cells during thymic or post-thymic development and maturation could lead to the absence of 
T cell help for HBsAg-specific B cells in these individuals. It is known that HLA molecules can operate in a 
second way to mediate the immune response, i.e. through the selection of T cells in the thymus or peripheral 
lymphoid organs with specific T cell antigen receptor (TCR) molecules. The available T cell receptor repertoire 
is partly determined by the positive and negative selection in the thymus. In this selection, T cells reactive with 
self antigens are deleted. We reasoned that the majority of DR3- and DR7-restricted HBsAg-derived T cell 
epitopes are not recognized as foreign because they contain or mimic self-related sequence patterns.  
 In contrast to e.g. DR1, for which many binding motifs were found in the HBsAg-sequence, only few DR3 
and DR7 binding motifs were identified. We thus assume that the diversity of DR3/peptide and DR7/peptide 
combinations is very limited. This makes the 'hole in the T cell repertoire'-hypothesis acceptable.   
 Remarkably, after numerous attemps in many different individuals, we were able to generate DR3- and DR7-
restricted HBsAg-specific T cell lines. It is conceivable that, in some individuals, there are T cells recognizing 
the (DR3/peptide or DR7/peptide) complex. This can be due to the absence of the responsible self-protein in 
these individuals. In this context, the finding of gene complementation in HBsAg-nonresponsiveness can be 
valuable.  
 In conclusion, some HLA molecules associated with nonresponsiveness are unable to present HBsAg-
peptides, others can, but in combination with certain HBsAg-mimicking molecules (polymorphic self, such as 
HLA molecules, or non-self, such as bacterial proteins), there is a hole in the T cell repertoire for recognition of 
these HLA molecules and no or very little T cells recognizing these complexes will be found in the periphery. If 
this hypothesis turns out to be correct, it remains to be established which is (are) the 'tolerogenic' self-antigen(s) 
that is (are) interacting with DR3 and DR7. In an attempt to unravel this molecular mimicry, all currently known 
polymorphisms of the human MHC are at present screened for AA homology with HBsAg (or known T cell 
epitopes) using a protein database (Swissprot). 
 We assume that the magnitude of the humoral anti-HBs response of one individual is largely dictated by the 
strength of his/her HBsAg-specific T cell response. The latter will depend on the quantity and quality of the 
(HLA-class II/HBsAg-derived peptides) complexes presented on the surface of the APC's. When these 
complexes are made of HLA molecules associated with good response (HLA-DR1, HLA-DP4,..) a vigourous 
response follows. If the complexes are of poor responder nature (HLA-DR3,-DR7, DP11,..) no or a very poor 
response ensues. Mixed presentation of poor and good responder HLA molecules tends to be sufficient to 
induce adequate responses. This view is supported by our observation of polyclonal and polyspecific T cell 
responses in good responder vaccinees: numerous AA sequences are recognized in association with different 
HLA-restricting elements. This is also termed antigen and epitope spreading. The ability to present a wide range 
of peptides leads to a more effective immune response. It can be accomplished through the availability of 
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multiple 'participating' HLA molecules. On the other hand, HBsAg-specific T cell responses in poor responders 
are difficult to reveal and are restricted towards a limited number of epitopes. This pauciclonality can be 
explained by the scarceness of 'participating' HLA molecules. We assume that normally responders posses a 
broad T cell repertoire, and NR a narrow one. The limited heterogeneity of the responses observed in NR can 
partly be attributed to the frequently observed homozygozity in these individuals. Especially individuals 
homozygous for HLA-DR3, -DR7 or -DQ2 are known to be nonresponders. 
 It can be concluded that T cells play a very important role in the generation of an adequate response towards 
the HBsAg. A defect in the HBsAg-specific T cell population might therefore be the most likely explanation for 
the existence of nonresponsiveness. Although the mechanisms mentioned above, might be valid, some 
arguments remain speculative and need to be confirmed. Therefore, further studies are needed to explore the 
exact nature of this T cell deficiency in HBV vaccine recipients. Further studies could be focussed on the role of 
professional APC, i.e. dendritic cells, in the generation of NR, since these cells not only play a role in the 
induction of T and B cell responses but also in the induction of anergy and tolerance. The extraction of HBsAg-
derived peptides out of HLA molecules and their identification can also shed a new light on the mechanism of 
HBsAg-nonresponsiveness. 
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Abbreviations 
AA  amino acid 
Ab     antibody 
Ag   antigen 
ALT   alanine aminotransferase 
anti-HBc   antibody to hepatitis B core antigen 
anti-HBe antibody to hepatitis B e antigen 
anti-HBs   antibody to hepatitis B surface antigen 
APC    antigen-presenting cell 
AST   aspartine aminotransferase 
BLV   bovine leukemia virus 
BSA    bovine serum albumin 
CAH    chronic active hepatitis 
CC  chronic hepatitis B virus carrier 
CD     cluster of differentiation  
CFA    complete Freunds adjuvant 
CH  chronic hepatitis 
CPH   chronic persistent hepatitis 
cpm    counts per minute 
CsCl   cesium chloride 
CTL    cytotoxic (cytolytic) T lymphocyte(s) 
DMSO   dimethylsulfoxide 
DNA    deoxyribonucleic acid 
EBV    Epstein-Barr virus 
EDTA    ethylenediaminetetra-acetic acid 
ELISA   enzyme-linked immunosorbent assay 
ER     endoplasmatic reticulum 
FACS    fluorescence-activated cell sorting 
FCS    fetal calf serum 
FITC  fluorescein isothiocyanate 
FSC   forward scatter 
g     gravity 
G145R  mutation from glycine to arginine at  
   AA position 145 of HBsAg 
gD2   Herpes simplex glycoprotein D2 
GMT    geometric mean titer 
gp     glycoprotein 
H-2   major histocompatibility complex of  
   mice 
HB  hepatitis B 
HBcAg   hepatitis B core antigen 
HBeAg   hepatitis B e antigen 
HBIG  hepatitis B immune globulin 
HBsAg   hepatitis B surface antigen 
HBSS    Hanks balanced salt solution 
HBV    hepatitis B virus 
HBVenv hepatitis B virus envelope 
HBxAg   hepatitis B x antigen 
HCC    hepatocellulair carcinoma 
HIV   human immunodeficiency virus 
HLA    human leukocyte antigen 
HR  high/good responder vaccine recipient 
HSV    herpes simplex virus 
3H-TdR  tritiated thymidine deoxyribose 
Ia    MHC class II histocompatibility 
     molecule of mice 
IFA    incomplete Freunds adjuvant 
IFN    interferon 
Ig     immunoglobulin 
IL     interleukin 
i.m.    intramuscular 
Ir    immune response 
ISI     integrated stimulation index 
IU     international unit 
kD     kilodalton 
LiPA  Line Probe Assay 
LPS   lipopolysaccharide 
LTT   Lymphocyte transformation test 
2-ME    ß-mercaptoethanol 
mAb    monoclonal antibody 
MHC    major histocompatibility complex 
MHR  major hydrophilic region 
MLR    mixed lymphocyte reaction 
MW    molecular weight 
n    number in study or group 
NA     not applicable 
ND     not determined 
NK    natural killer  
NR  non/poor responder vaccine recipient 
n.s.   not significant 
OG   ß-D-octyl glucoside 
ORF   open reading frame 
P    probability 
PBL    peripheral blood lymphocyte(s) 
PBMC   peripheral blood mononuclear cell(s) 
PBS    phosphate-buffered saline 
Pc    corrected P value 
PCR    polymerase chain reaction 
PDV   plasma-derived hepatitis B vaccines 
PE   phycoerythrin 
PHA    phytohemagglutinin 
PHC   primary hepatocellular carcinoma 
PI    propidium iodide 
PWM  pokeweed mitogen 
r     recombinant 
R    responder vaccine recipient 
rad    radiation  
 
 
 
RIA    radioimmunoassay 
RNA    ribonucleic acid 
rpm   revolutions per minute 
RPMI    Roswell Park Memorial Institute 
RR  relative risk 
SD     standard deviation   
SDS-PAGE   sodium dodecyl sulfate polyacryl- 
    amide gel electrophoresis 
SI     stimulation index 
SSC   side scatter 
TCR    T cell receptor  
Th cells   T helper cells  
TNF   tumor necrosis factor 
TT     tetanus toxoid 
U     unit 
UV     ultraviolet 
v/v     volume/volume 
VZAg  varicella/zoster virus antigen 
WHO  World Health Organisation 
w/v    weight/volume 
YDV   yeast-derived hepatitis B vaccines 
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Figure 1: World-wide endemicity of hepatitis B virus. Adapted from WHO Europe - Viral Hepatitis Prevention Board-
European Occupational Health Series n°8 [10]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: The genomic map of the hepatitis B virus. The viral DNA is partially double-stranded (red circle). The long 
strand of fixed length (blue circle) encodes seven proteins from four overlapping reading frames (surface [S], core [C], 
polymerase [P], and the X gene [X], shown as large arrows, and three upstream regions (preC, preS1, and preS2). A 
protein is covalently linked to the 5'end of the long strand (hatched blue oval) and a short oligoribonucleotide at the 5'end 
of the short strand (red zigzag). The size of each segment is shown in parentheses. The diagram is adapted from Lee WM, 
1997, [4]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Structure of the hepatitis B virion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Representation of the antigen and polypeptide composition of envelope and nucleocapsid proteins of intact 
virions and spherical and filamentous subviral particles. L, large; M, middle; S, S-region (adapted from Milich DR, 1997, 
[18]) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: The three different forms of hepatitis B surface antigen. Details of the surface protein structure are shown 
(adapted from Lee WM, 1997, [4]). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6a: Secondary structure model for the arrangement of the small envelope protein in 22 nm particles. The predicted 
four membrane spanning segments project the N- and C-termini of S on the outer surface of the particle. The partial 
glycosylation at position 146 is indicated by (¥)(adapted from Stirk HJ, et al., 1992, [25]). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6b: Proposed model of major hydrophilic region (MHR) indicating cysteine (black circles) to cysteine disulphide 
bridging (/\/\/). The five antigenic regions are labelled HBs1 through 5 (adapted from Wallace LA, and WF Carman, 1997, 
 
 
 
[9]). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Estimated outcome of hepatitis B infection in adults. Annual estimated cases in the WHO European region. 
Adapted from Van Damme P, et al., 1995, [37].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Schematic representation of the structural features of major histocompatibility complex (MHC) class I and class 
II molecules. MHC class I molecules are anchored in the membrane by a single transmembrane segment contained in the 
45 kD α-chain. The MHC class I α-chain is noncovalently associated with ß2-microglobulin. There are four external 
domains, three of which contain intramolecular disulfide bonds, as shown. In contrast, MHC class II molecules consist of 
noncovalently associated α- and ß-chains, both of which are anchored within the membrane. The overall domain 
organisation, however, is highly similar. Glycosylation sites on both molecules are indicated by a solid circle.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Peptide (red) bound in the cleft of a HLA-class II molecule (blue) from human cells. This 'top view', probably as 
seen by T cells, is based on the X-ray crystallographic analysis of Brown and colleagues, 1993, [51]. The α1 domain helix 
 
 
 
is represented on top, the ß1 domain helix on the bottom. The ß-sheet is located on the bottom of the cleft.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Pathways of HLA class I (left panel) and II molecule (right panel) assembly and antigen processing. In the 
class I pathway, endogenously processed peptide is carried to the endoplasmic reticulum (ER) by putative peptide 
transporter molecules. There, the class I heavy chain and ß2-microglobulin combine to form the class I molecule. This 
dimer binds the processed peptide; binding of the peptide may occur as the class I molecule is being assembled. The class 
I-peptide complex then traffics through the Golgi and post-Golgi compartments and moves to the cell surface. At the 
surface, it is available to interact with T cells, facilitated by interaction with the CD8 molecule, which is to bind to the α3 
domain of class I molecule. This compartmentalised pathway apparently restricts the binding of class I molecules 
primarily to endogenous peptides; the binding interaction between the class I heavy chain and the CD8 molecule directs 
class I endogenous peptide complexes to interact with CD8+ T cells. In the class II pathway, class II α- and ß-chains are 
assembled in the ER along with the invariant chain, which is thought to interact in such a way that peptide cannot bind to 
the antigen-binding groove. Thus most endogenously processed peptides, which are transported to the ER are unable to 
bind to class II molecules. After transport through the Golgi and post-Golgi compartments, the class II α-ß invariant chain 
complex moves to an acidic endosome, where the invariant chain is proteolytically cleaved and released from the class II 
molecule. At this point, exogenously derived peptides which have been brought to the endosome through fusion of 
phagolysosomes or recycling endosomes may now bind to the class II molecule. This class II molecule-peptide complex is 
then transported to the cell surface, where it is available to interact with an appropriate T cell. The structure of the class II 
 
 
 
molecule allows preferential interaction with the CD4 molecule, which facilitates recognition between the class II peptide 
complex and an appropriate TCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Schematic presentation of T lymphocyte recognition of MHC class II molecule and peptide. The principal co-
stimulatory signal expressed on professional antigen-presenting cells is B7, which binds the T-cell protein CD28. Binding 
of the T-cell receptor (TCR) and its co-receptor CD4 to the peptide~MHC class II complex delivers a signal (signal 1) that 
can only induce clonal expansion of T cells when the co-stimulatory signal (signal 2) is given by binding of CD28 to B7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Regions in Europe covered by a policy of universal immunization (adapted from The Viral Hepatitis Prevention 
Board-Facts Sheet-1996, [127]). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Impact of immunisation strategies against hepatitis B: estimated proportions of cases of hepatitis B prevented 
based on various immunization strategies (adapted from Margolis H, et al., 1991, [129]). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Schematic and highly simplified representation of the human immune response to HBsAg. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Schematic presentation of the molecular basis of the HBV vaccine escape mutant. Anti-HBs made in response 
to a wild-type HBsAg vaccine recognizes and neutralizes wild-type HBsAg but not mutant HBsAg. Therefore, the HBsAg 
mutant can escape anti-HBs and establish a productive HBV infection despite successful vaccination against HBV 
(adapted from Blum HE, 1995, [288]). 
 
 
 
 
